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INTRODUCTION 
DEFINITION 
The term pars planitis should be used only for that subset 
ofIntermediate Uveitis where there is snow bank or snowball formation 
occurring in the absence of an associated infection or systemic disease (that 
is, "idiopathic"). If there is an associated infection or systemic disease, then 
the term Intermediate Uveitis should be used. According to the diagnostic 
criteria of the Standardization of Uveitis Nomenclature (SUN) Working 
Group, pars planitis is defined as the idiopathic Intermediate Uveitis 
associated with the presence of snow-banking and/or snowballs 
ANATOMY 
Uveal tract, the vascular middle layer of the eye comprises of iris 
anteriorly, ciliary body in the middle and choroid posteriorly. Ciliary body 
extends for 6mm from the root of iris to ora serrata. The anterior portion of 
the ciliary body is the pars plicata and consists of 70 – 80 ciliary processes. 
The posterior portion of the ciliary body is the pars plana which is a flat 
extension from the posterior aspect of ciliary process to the ora serrata. The 
area is about 3.5 – 4 mm in length. The pars plana has a smooth black 
surface marked only by faint striae running on from the teeth of ora serrata. 
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The epithelium lining the parsplana consists of an outer pigmented 
layer continuous with the pigmented layer of retina. The inner 
nonpigmented layer is columnar, becoming cuboidal over the ciliary process 
and flattens as they approach the ora serrata. Blood supply is by the long 
posterior and anterior ciliary arteries.  
Vitreous base is a zone 3 – 4 mm wide which straddles the ora serrata. 
As a result of strong adhesions of cortical vitreous at the vitreous base in an 
eye with PVD, the posterior hyaloid surface remains attached to the 
posterior border of vitreous base.  
HISTORY 
Intermediate uveitis (para planitis) was first described as chronic 
cyclitis by Fuch`s in 1908 (Kimura, et. al., Peripheral Retinitis and 
ChronicCyclitis in Children Trans Ophthal soc UK85: 39-52,1965). 
Schepens (in 1950) who is the pioneer of modern indirect ophthalmoscope 
and examination of peripheral retina by scleral depression, described them 
as peripheral uveitis. This was characterized by inflammation centered 
around the retinal periphery. Kimura presented the name “Chronic Anterior 
Uveitis”, to involve the intraocular inflammation primarily affecting ciliary 
body, anterior vitreous associated with optic disc changes and macular 
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edema. Nussenblatt in 1988 described pars planitis as an inflammation of 
the ciliary body, vitreous base and peripheral retina. 
CLASSIFICATION 
1.  The classification scheme recommended by the International 
uveitisstudy group is based on anatomical location. Intermediate 
uveitis formerly known as pars planitis is classified into 
a. posterior cyclitis 
b. Hyalitis 
c. Basal retinochoroiditis 
2.  TERSLER (classification and symptoms and signs of uveitis :Duane) 
has classified intermediate uveitis into 
a. Cyclitis 
b. Vitritis 
c. Pars planitis 
3. Based on clinical presentation BOKE classified pars planitis into 
a. Diffuse inflammatory type : characterized by dust like opacities in 
vitreous, most prominent inferiorly called snow ball opacities. 
b. Exudative type:  with presence of heavy confluent exudate over 
pars plana and ora serrata. It is often associated with PVD. 
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c. Vasoproliferative type : characterized by sheathing, perivascular 
cuffing and partial occlusion of peripheral vessels. This is more 
prone for developing disc edema, optic atrophy and optic disc 
neovascularization. Chronic poorly controlled intermediate uveitis 
often had total retinal detachment, proliferative vitreoretinopathy 
or cyclitic membrane with ciliary body traction and hypotony  
(Pederson).Slovak further divided the diffuse inflammatory type of 
parsplanitis into 
a. Serous type in which pars plana is not grossly involved. 
b. Infiltrative type which presents with small white spots 
involving the pars plana.  
Both the serous and infiltrative type can progress to exudative type. 
3. BROCKHURST in 1960 classified 5 possible types of intermediate 
uveitis: 
i. Benign course in which inflammation subsided without any 
intervention. This type comprised of 28 – 31 % of patients with 
parsplanitis 
ii. Patients who developed choroidal and serous retinal detachments. 
They accounted for 12% of patients with pars planitis. 
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iii. Those who developed vascularized high snow banks that 
eventually formed cyclitic membranes leading to retinal 
detachments or glaucoma. They formed 6% of group with pars 
planitis. 
iv. Those who developed significant vascular obliteration that led to 
visual field loss and optic atrophy , were around 8%. 
v. 46% of patient had chronic smouldering course. 
BROCKHURST further condensed his classification into four groups 
in 1980 as30: 
a. Benign : 31% 
b. Mild chronic : 49% 
c. Severe chronic : 15% 
d. Relentlessly progressive : 10% 
4. KIMURA classified pars planitis into  
a. Mild : characterized by absence of keratic precipitates  
        : faint or absent flare, cells less than 5 
         : Anterior vitreous floaters 1 + or 2+ 
         : Slight edema of posterior retina and no exudates  
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b. Moderate    : had no keratic precipitates 
                   : Faint or no flare  
                   : cells 5 – 10 (1+) 
                   : Vitreous floaters: scattered fine and coarse 
        Opacities obscuring fundus 
                   : Moderate edema of posterior retina and exudate 
        over the inferior pars plana 
c. Severe   :   characterized by small to medium sized white            
         KP`s, with a few mutton fat KP`s   
  on gonioscopy. 
                    :  Moderate to marked flare, 10 – 20 cells per field. 
                    :  Anterior vitreous cells were dense enough to 
preventa view of the fundus (3 – 4 +)  
      :  marked posterior retinal edema, peripheral 
vascular sheathing and pigmentary changes in 
peripheral retina. 
5. Standardization of uveitis nomenclature (SUN) working  group 
anatomic classification of uveitis classified intermediate uveitis into 
a. Pars planitis 
b. Posterior cyclitis  
c. Hyalitis 
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EPIDEMIOLOGY 
Pars planitis accounts for 4 – 15 % of uveitis patients in referral 
practice and constitutes about 91 % of intermediate uveitis 
AGE 
It primarily affects children and young adults. There is a bimodal 
distribution with one peak in the second decade and another peak in the 
third or fourth decade. 
In the pediatric age group, intermediate uveitis is associated with a 
worse presenting visual acuity. Poorer outcomes may be related to delayed 
presentation/diagnosis, the inherent difficulties of immunosuppression in 
children, or a more aggressive disease. 
SEX AND RACE 
There is no sex or race predisposition. A common immunogenetic 
predisposition to multiple sclerosis and pars planitis was found to be 
associated with the HLA-DR15 allele. In a prospective study of 53 patients 
with pars planitis by Raja et al, an association was found with the HLA-
DR15, a subtype of HLA-DR2. Other associations include HLA-A28, HLA 
–DR51, HLA-DR17, HLA-B8, and HLA-B51. In addition, TT homozygotes 
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for the interferon-gamma (INF-gamma) gene may be at a higher risk of 
disease development and may also run a more severe course. 
CLINICAL MANIFESTATION 
Pars planitis is one of the most underdiagnosed uveitic entity. This is 
due to the lack of expertise in indirect ophthalmoscopy on patients with 
anterior uveitis and vitreous floaters. There is also lack of awareness and 
misconception about this entity. Most often it is labeled as cyclitis, posterior 
uveitis and vitreous haemorrhage. 
PATIENT`S SYMPTOMATOLOGY 
Patients usually have very few complaints initially. Most of them 
present with blurring of vision and floaters. In pars planitis cases unlike 
other uveitic conditions the eye rarely becomes red and painful. There is 
usually no gross reduction in vision. 
70 – 80% of patients have bilateral signs at the time of presentation, 
even though most of them are usually symptomatic only in one eye. One 
third with unilateral disease will subsequently develop bilateral 
involvement. 
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ANTERIOR SEGMENT 
Anterior segment inflammation is mild and is more common in 
children and patients with multiple sclerosis. Occasionally patients present 
with pain and photophobia and later develop signs of intermediate uveitis.  
Aqueous flare is usually minimal. They rarely exceed 20 cells per 
field, and moderate flare. Kimura described the keratic precipitates as small 
or medium sized and white, even though gonioscopy may reveal a few 
mutton fat keratic precipitates. Brockhurst noted peripheral anterior 
synechiae in 24% of cases and posterior synechiae in 18%31. Children had 
band keratopathy. Khadodost demonstrated areas of peripheral corneal 
oedema with keratic precipitates at border between oedematous and normal 
cornea in 4 out of 10 patients. Autoimmune endotheliopathy is a rare 
finding. Anterior uveitis can occur due to spill over of inflammation from 
the parsplana and is typically non granulomatous. Brockhurst described the 
early parsplana inflammation to consist of yellowish grey globular exudates 
on the parsplana, ciliaris, at ora serrata and anterior portion of retina. These 
exudates are also seen at the filtration angle. They may hide the normal 
landmarks of the angle and ora serrata. 
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 Chronic cyclitis as described by kimura showed varying number of  
finedust like opacities in the anterior vitreous, coarser opacities were 
observed later when vitreous degeneration also occurs. 
FUNDUS 
Fundus examination showed the presence of vitreous cells in almost 
all cases of active pars planitis. The vitreous opacities which consist of 
vitreous cells and debris with macrophages typically are seen as multiple 
snow ball opacities in the peripheral fundus. 
Ahens and Sound macher described yellowish grey exudates in the 
inferotemporal ora serrata and parsplana. Brockhurst noted that these 
exudates coalesce to form the material commonly described as 
snowbanking. Snow banking is usually seen in the parsplana region and ora 
serrata inferiorly. They are usually discontinuous and form a thin or broad 
band extending into the peripheral retina. Even though this material has 
been often termed exudates, Nussenblat considers them to be most probably 
fibroglial scars32. Neovascularization associated with it can predispose the 
patient to vitreous haemorrhage. Pars plana exudates commonly described 
as snow banking is considered to be the hall markof the disease. Pars plana 
exudates are not mandatory for the diagnosis of pars planitis. Henderly, et. 
al, have found that 24% of patients with pars planitis can have vitreous cells 
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in the other eye which is probably the early sign of this disease. The 
presence of snow bank has been found to correlate with the severity of the 
disease. An increased incidence of cystoids macular oedema has been 
reported in eyes of pars planitis with snow banks. 
Abnormality of Retinal Vessels 
 Peripheral retinal vascular abnormalities characterized by sheathing 
and obliteration of small peripheral venules can be seen. Periarteritis is less 
common. Peripheral neovascularization can evolve into a vascular cyclitic 
membrane. Vitreous haemorrhage is rare sequelae. Retinal venous dilatation 
predominantly involving the inferior branch is also associated with edema 
of posterior retinal oedema. It is more common in children5. 
Pigment clumps may be seen in peripheral fundus surrounding a 
depigmented zone. An active chorioretinitis is rare in these cases, even 
though Welch has mentioned of its existence. A careful examination of 
macula is important in patients with parsplana exudates and paravenous 
oedema. 
Macula 
Macular changes are quite commonly seen in these patients. The 
incidence is as varied as from 20-80%. Malinowswki reported macular 
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changes in 28% of cases (Malinowwski, SM, Pulido, JS, Long-term Visual 
Outcome and Complications Associated with Pars Planitis Ophthalmology 
1993: 100: 818-825). Some reports 24.8% with varied macular pathologies, 
most of them being cystoid macular oedema. Hogan and associates reported 
incidence of 50% with macular oedema (Hogan, MJ, Kimura, SJ, Peripheral 
Retinitis and Chronic Cyclitis in Children Trans Ophthalmol Soc: UK 85: 
39-52, 1965). Early macular oedema has loss of foveal reflex with a wet 
appearance to posterior pole and numerous glistening highlights reflected 
from the irregularly thickened oedematous retina. Kimura also descried 
macular oedema in 50% of cases. Severity of macular oedema depends on 
the severity of pars planitis characterized by heavy vitreous reaction and the 
presence of parsplana exudates throughout the peripheral retina and ora 
serrata. 
Long standing macular oedema can lead to epithelial stippling in 
macula and may be a subtle sign of previous oedema in chronic cases of 
intermediate uveitis. Unfortunately this polycystoid macular degeneration 
can be the cause of severe visual loss in these patients5.Loss of visual acuity 
is usually not present in the milder form of this disease but early profound 
loss of visual acuity is most commonly associated with cystoid macular 
edema. 74% patients with CME had poor visual acuity. The severity of 
reduction of visual acuity depends on the duration and extent of cystoid 
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macular edema. Disc edema was found in one third of cases. Disc edema 
was always associated with macular edema in pars planitis according to 
kimura. Fluorescein Angiography shows late staining of dye around the 
FAZ, and reduction of FAZ in macular edema. Fundus Angiography 
showed petalloid hyperfluorescence in cystoid macular edema5. 
Rhegmatogenous retinal detachment associated with vitreous traction 
is not uncommonly found in pars planitis. The incidence reported varies 
from 3% by Brockhurst to 22% by Smith, et. al, Nussenblat is of the opinion 
that the presence of retinal detachment may reflect the positive effect of 
therapy with corticosteroids. He also is of opinion that the varied range of 
incidence of retinal detachment is because of the predominantly retinal 
practice by Brockhurst.  
Optic disc edema, optic atrophy and optic disc neovascularization has 
been reported in patients with intermediate uveitis. Chronic poorly 
controlled pars planitis often times had total retinal detachment and 
proliferative vitreoretinopathy due to the formation of cyclitic membrane 
and subsequent ciliary body traction. Pederson reported the presence of 
hypotony in these patients. 
Brockhurst presented 2 varied type of presentation of pars planitis. 
95% patients of 30 years of age predominantly had annular involvement of 
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parsplana ciliaris. The chief finding was a peripheral choroidal detachment 
on all quadrants. 
Malignant progressive form of peripheral uveitis was present in 
patients who were under 15 years of age and was characterized by 
development of massive yellowish grey exudate and new vessels from 
ciliary body, but not from retina and forming a cyclitic membrane. 
Associated with this, later the cyclitic cicatrizing membrane adherent to 
retinal periphery gives rise to retinal detachment. Further cicatrization pulls 
the lens-iris diaphragm forward causing secondary glaucoma. 
Even though inflammatory signs shows partial remission most studies 
gives very low incidence of permanent remission. Smith found only 
5%remission rate when he followed the patients from 4-6 years. Hogan 
reported only one remission from 56 cases which he followed from 1-9 year. 
Aaberg states that only very rarely does one observe a permanent resolution 
of the disease. 
SYSTEMIC ASSOCIATIONS 
Pars planitis can exist as an isolated idiopathic disorder or can be 
associated with other diseases. Zieshut found that 9.7% had associated 
sarcoidosis (Henderly, DE, Changing Patterns of uveitis, Am.j. ophthalmol). 
In India 13 cases of pars planitis with sarcoidosis was reported from 
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Sankara Nethralaya. Majority of the patients had associated granulomatous 
uveitis. Recent reports indicate that 14.8% of patients with pars planitis 
develop multiple sclerosis over 7 years follow up. 
Lyme disease caused by Borrelia burgdorferi and transmitted by 
Ixodestick seems to be associated with pars planitis. Friedman reported 5 
cases with lyme disease. 
Boskovich noted systemic disorders in 26 out of 83 patients with pars 
planitis.  
Out of 26, 10 had presumed sarcoidosis, 6  had multiple sclerosis, 2  
had optic neuritis, 2  had inflammatory bowel disease, 4  had thyroid 
abnormalities, 2  EBV infection. 
DIFFERENTIAL DIAGNOSIS 
1. VITREOUS OPACITY 
Posterior uveitis 
Endophthalmitis 
 Amyloidosis 
 Reticulum cell sarcoma 
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2. PERIVASCULITIS 
Eales disease 
Sarcoidosis 
Behcet disease 
3. PERIPHERAL GRANULOMA 
 Toxocara 
4. SPILLOVER ANTERIOR UVEITIS 
 Non granulomatous anterior uveitis 
PATHOLOGY 
Gross examination reveals extension scars over the pars plana region. 
Microscopy of snow ball opacities shows epitheloid cell granulomas. 
Peripheral snow banking reveals, thick connective tissues consisting 
of glial cells including fibrous astrocytes and scattered inflammatory cells 
predominantly lymphocytes. The paucity of inflammatory cells indicate that 
the presence of snow bank is rather suggestive of a chronic inflammation 
with reactive changes than an acute inflammation32. 
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Immunopathologic study of snow bank over pars plana showed a ratio 
of helper/inducer cells to suppressor/cytotoxic cells to be 10:122. This 
pattern of CD4:CD8 is also seen in multiple sclerosis. Most of these 
lymphocytes were found to bear class II HLA antigen. 
Muller cells proliferate in response to factors produced by activated 
lymphocytes, suggesting a means of snow bank formation. In tissues muller 
cells express MHC class II molecules and present to T cells, contributing to 
inflammation. Type IV collagen and laminin were the major collagen 
glycoproteins in this snow bank. High ratio of suppressor/helper cells 
suggests an active T cell mediated process in the eye. 
Aetiopathogenesis 
 The cause of pars planitis has not been elucidated. The inferior 
location of snow banking is attributed to gravity. Gartner suggested that it 
may be due to the more number of vitreous cells normally present in the 
regions inferiority. 
Davis proposed two stage disease process of which stage(1) is 
immunologically mediated and stage (2) is non-specific breakdown of 
intraocular regulatory mechanism resulting in chronic inflammatory disease 
(Nozik, Uveitis: A Clinical Approach in Diagnosis and Management 2nd 
Edition 166-170). Descheren attributes a diffuse phlebitis and subsequent 
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breakdown of blood ocular barrier. This causes release of inflammatory 
cells, cytokines and other inflammatory mediators that settle inferiorly. 
Khadodaust had hypothesized that intermediate uveitis is primarily 
vitreal inflammation which starts adjacent to involved vascular tissue.  
Injection of hyaluronic acid into the vitreous of monkey produced a 
clinical picture of pars planitis. 
Gartner demonstrated that the vitreous cellular remnants near the 
vitreous base may be the antigenic stimulus in pars planitis. 
Kaplan noted a protein P36 in the serum of patients with active pars 
planitis that may be a marker of the disease. Several other studies have 
revealed several immunological abnormalities in the serum with pars 
planitis. Rahi, et. al, found decreased levels of complement C3 in the serum 
of pars planitis patients Kaplan noted that the normal T cell regulation of B 
cell function is deranged, because they observed a relatively increased 
number of B cells and null cells in comparison to T cells in the aqueous and 
vitreous of patients with pars planitis. Retinal S antigen which is located in 
the plasma membrane of the photoreceptors of retina and having 
uveitogenic property is increased in patients with pars planitis. Intercellular 
adhesion molecular (ICAM-1) was raised in a considerable number of 
patients with pars planitis. Increased serum antibody to Retinal S Antigen, 
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serum immunoglobulin and circulatory immune complexes associated with 
HLA-DR2 antigen and presence of familial incidence that a complex 
immunological process is involved in the pathogenesis of this disorder. The 
specific cause of this disease is most probably multifactorial and probably 
differs from case to case. 
Treatment 
 As no specific etiology is found, the treatment of this condition 
remains non specific. The disease is by nature slowly progressive. The role 
of treating mild vitritis, mild periphlebitis and early mild cystoids macular 
edema with good vision, with aggressive anti-inflammatory therapy is 
unknown. 
Kaplan advised treatment of patients with 
1. Visual Acuity of less than or equal to 6/12. 
2. Eye with extensive neovascularization and snow banking 
3. With substantial vasculitis. 
Medical Treatment 
 Topical steroids are not effective except in aphakic patients with 
mildvitritis. Periocular steroids with depot Triamcianalone is tried twice or 
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thrice weekly over a 6-8 week period. They are effective in treating 
uniocular disease. 
Systemic steroids of Prednisolone at 1mg/kg/day is given for5 
1. Bilateral disease 
2. Ocular disease resistant to periocular steroids. 
Immunosuppressives 
 Cyclosporine is used as a steroid sparing agent for 
1.  Resistant cases to steroids or 
2. Patients with long term side effects to steroids 
Nussenblat described these indications and found out that 
cyclosporine is effective in the treatment of pars planitis. 
Major side effect of cyclosporin is the renal toxicity and hypertension 
(Nussenblat, uveitis: Fundamentals and Clinical Practise 286-287). 
Azathioprine at a starting dose of 50mg thrice daily with gradual 
tapering is effective in patients who are resistant to corticosteroids. 
Various other immunosuppressives like cyclophosphamide, 
chlorambucil and methotrexate have been tried. 
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Cryotherapy 
 Cryotherapy applied to the parsplana exudates is thought to be 
effective in treatment of Pars planitis. Aaberg reported success with 
cryotherapy on steroid resistant cases in 1973. Aaberg believes that cryo 
application to the exudate destroys the vascular component of peripheral 
retinitis or vitrits and eliminates the entrance sites of inflammatory 
mediators into the eye (Asberg, TM, Cesarz, et. al., Treatment of Peripheral 
Uveitis by Cryotherapy Am.J.Ophthalmol 1973, 75: 685-688). Devenyi is of 
opinion that it is necessary to ablate the new vessel and periphlebitis, rather 
than areas of exudation, this destroys the neovascularization and the 
ischaemic tissues, nussenblat is of the opinion that the effect is evident 
within several weeks and lasts for 2-6 months. A second treatment may be 
given if the 1st treatment was effective. Devenyi reported the use of 
cryotherapy in 27 eyes in 18 patients with steroid resistant pars planitis and 
claimed that vitritis was eliminated in 75% with a follow up of 2-12 years. 
In 90% of patients steroids were not needed after cryo application was done. 
67% of patients demonstrated improvement in visual acuity on an average 
of 3 lines. 85% needed only 1 treatment, 11% needed 2 sittings and 4% 
needed 3 sittings before regression of neovascularization was achieved. 
Aaberg treated patients who were not responding to 80-100mg of 
prednisolone and 80mg depot Medrol posterior subtenons every 2-4 weeks 
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for 6 months, and these patients not undergoing remission in 6 months with 
cryo application. End point was the appearance of an iceball which engulfed 
exudative focus over the probe tip. After brief thawing the same area was 
immediately refrozen to the same degree. Further all areas of inflammatory 
response were also treated. 35% of patients remained inactive for 14 
months. 57% of patients had marked decrease in activity requiring no 
corticosteroid therapy. Complication includes transient increase in vitreal 
inflammation, decreased accommodation, cataract and hyphaema. There had 
been reported increase of post treatment retinal detachment.  
After ruling out infectious causes of IU, the following (modified 
Kaplan’s) algorithm is suggested 
Step  1.   Periocular steroids administered by local injection of depot 
Corticosteroids may be repeated every 4 weeks until 3-4 injections have 
been administered. Generally the inflammation responds and the CME 
improves. (Intravitreal triamcinolone (IVTA) may be an alternative to 
periocular injections in refractory cases.). The procedure followed is 
described by Nozit. The cotton tipped applicator soaked in 4% lignocaine 
hydrochloride is applied over the upper outer quadrant (superotemporal). 
Using a 26 gauge 5/8 inch needle with the bevel facing up,   the needle is 
advanced posteriorly with a broad side to side slow posterior movement 
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following the curve of the globe, taking care that the globe does not move 
with the needle. The bevel end is rotated downwards and 0.75 – 1ml of 
steroids is injected as posteriorly as possible to reduce the risk of steroid 
induced glaucoma. 
Step   2. If local therapy is not effective or bilateral severe disease is 
seen at presentation oral corticosteroids prednisolone 60-
80mg/day are indicated. 
Step   3. Systemic immunomodulatory therapy is indicated in the 
treatment of bilateral disease, and can be considered if 
corticosteroids fail, are not tolerated or contraindicated 
Step   4.  If corticosteroids fail, or if corticosteroids and 
immunomodulatory therapy are contraindicated, and if pars 
plana snowbanks are present, peripheral ablation with 
cryotherapy or indirect laser photocoagulation to the peripheral 
retina can be done. 
Step 5.  If all the treatment modalities fail to control inflammation, 
parsplana vitrectomy with induction of posterior hyaloidal 
separation and peripheral laser photocoagulation to parsplana 
snowbank may be performed, along with immunomodulatory 
therapy. 
 
 
  30
 
                         INTERMEDIATE 
 
   
       Mild      Moderate to Severe 
Vision more than or 6/12 Vision less than 6/12 or equal to       
6/12 and/or with CME 
 
No treatment Periodic observation  
Periocular depot of steroids 
    
      Not Responding 
  
 Add systemic steroids 
         Not Responding 
  
Immunosuppressives 
      Not Responding 
  
Vitrectomy 
         Not Responding 
  
Cryotherapy to vitreous base 
 
CATARACT EXTRACTION IN PARS PLANITIS  
The eye should be quiet for at least 3 months prior to surgery. 
Preoperative systemic steroids of 40 – 60 mg per day and posterior subtenon 
injection of depot steroid 3 – 4 days prior to surgery is preferred.  
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Phacoemulsification with IOL implantation in eyes with pars planitis 
is reported to be safe leading to good visual outcomes in most cases11. The 
factors in surgical success were control of inflammation, meticulous 
surgery, in-the-bag IOL implantation, and vigilant postoperative care.The 
frequent cause of poor visual recovery was CME, submacular fibrosis, and 
epiretinal membrane. Absolute control of inflammation in patients with pars 
planitis through a stepladder approach may reduce the incidence of cataract 
development, and can certainly improve visual rehabilitation after cataract 
extraction. Implantation of a posterior chamber lens can be well tolerated in 
selected cases. Careful patient selection, coupled with the use of an 
appropriate surgical technique, appear to be of major importance. 
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AIM OF THE STUDY 
 
 
1. To find out the prevalence, the clinical profile and response to therapy 
in patients with pars planitis. 
 
 
2.  To identify different modes of presentation and a comparison was 
made with other studies. 
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METHODS AND MATERIALS 
Fifty cases of pars planitis who attended the uvea clinic of the 
Regional Institute of Ophthalmology from March 2009 to September 2010, 
were taken up for this study. 
The main criteria of diagnosis were 
1. Presence of vitreous cells and / or vitreous opacities in the vitreous 
base adjoining the pars plana and peripheral retina. 
2. Absence of predominant anterior segment inflammation 
characterized by cells of more than 2+ and KP`s of more  
than 2+. 
3. Presence of snow ball opacities and snow banking with peripheral 
vasculitis signs, like periphlebitis and paravenous oedema were 
considered to be the hallmark of pars planitis, eventhough they 
were not considered essential for the diagnosis of parsplanitis. 
Patients with following conditions were excluded 
1. Anterior segment predominantly involved with more than 2+ 
cells and 2+ KP`s. 
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2. Active posterior segment inflammation like retinochoroiditis in 
the posterior pole. But patients with central retinal leaks alone 
on FFA were not excluded from the study. 
3. Patients with signs of active tuberculous choroiditis and other 
signs of granulomatous uveitis, were excluded from the study. 
4. Patients who showed peripheral tubercles and lesions 
suggestive of Toxocariasis and Toxoplasmosis were excluded 
from the study. 
The presenting complaints of the patients were sought for and the 
laterality of the symptoms was noted. Patients were encouraged to quantify 
the loss of vision and the hazy vision. Patients who complained of vitreous 
floaters were asked for the laterality of the symptoms and history of flashes 
of light, or trauma before the onset of floaters.   
A negative history of symptoms of anterior uveitis like redness, pain 
and photophobia were asked for. A careful history of systemic 
manifestations of sarcoidosis like wheezing, rashes and arthritis was asked 
for. A family history of similar complaints was asked. A diligent search was 
made to find out any etiological factor or aggravating factor in the history of 
the disease. 
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PERSONAL HISTORY 
1. Ocular Toxoplasmosis and Toxocara were suspected in patients 
coming into close association with pets. 
1. Dietary history was taken. 
2. Prevalence of Hypothyroidism, Diabetes mellitus and 
Hypertension were asked for. 
3. Family history of Glaucoma was asked before the patient 
was started on steroids. 
4. Before considering FFA the females were asked about the 
menstrual habits and pregnancy. 
DEMOGRAPHIC FACTORS 
Age and sex of the patients were noted. 
CLINICAL SIGNS 
The patients who were suspected to have pars planitis based on the 
complaints of blurring of vision with floaters with very rare complaints of 
redness, watering and photophobia were subjected to clinical examination to 
rule out pars planitis. 
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Slit lamp examination was done and flare and cells were graded as per 
the grading by the Standardization Of Uveitis (SUN) working group. 
I. FLARE 
 
Flare              Description 
 
0                      None  
 
 1+                           Faint 
 
           2+              Moderate (iris and lens details clear) 
 
           3+               Marked (iris and lens details hazy) 
 
    4+                        Intense (fibrin or plastic aqueous) 
 
 
II. CELLS 
      Grade                                           Cells in field 
 0                                                        <1 
 0.5+                                                 1 – 5 
 1+                                                   6 – 15 
 2+                                                   16 – 25 
 3+                                                    26 – 50 
 4+                                                      >50 
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III. KERATIC PRECIPITATES 
Keratic precipitates were categorized on the basis of size (as small, 
medium and large), shape, colours (fresh - white and round, old – shrunken 
and pigmented) and appearance (mutton fat KP`s signifying granulomatous 
uveitis and white round KP`s non granulomatous). 
They were further graded as 
                                                                         Per field 
            1 +                                                           5 - 1 0 
            2 +                                                          11 - 20     
            3 +                                                           21 – 50 
            4 +                                                             > 50 
 
Patients who presented with signs of predominant anterior segment 
involvement i.e. ., cells and KP`s over 2+ and flare more than 3+ were 
excluded from the study, as it was presumed that the intermediate uveitis 
seen along with the anterior uveitis, is due to the spill over from 
iridocyclitis. Further granulomatous uveitis without signs of systemic 
sarcoidosis was also excluded from the study. 
Gonioscopy was done on all patients to rule out the presence of KP`s 
at the Angle and Peripheral anterior synechiae. The angle was graded on all 
patients with raised intraocular tension by Shaffer system as 
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Grade 4: 35 - 45°  -  Ciliary body can be visualized 
Grade 3: 20 - 35°  -  Scleral spur can be identified.  
- It is incapable of closure 
Grade 2: 20°  - Trabeculum can be identified 
   - Moderately narrow angle 
  - Angle closure is unlikely 
Grade 1: 10°  - Only schwalbe`s line visible 
- Angle closure is not inevitable even though 
risk is high 
Slit angle        - No obvious iridocorneal contact 
    - No angle structure identified 
-  Angle has greatest danger of imminent 
 closure 
Grade 0         -  Closed angle resulting from   
     iridocorneal contact 
Patients with IOP of over 20 mm Hg by schiotz were  subjected to 
detailed evaluation for glaucoma at the glaucoma clinic of Regional Institute 
of Ophthalmology.  
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IV. VITREOUS CELLS 
Vitreous cells were graded with Hruby lens examination by 
retroillumination, cells appear as back dots, debris is often pigmented and 
forms clumps. 
GRADE                 VITREOUS CELLS 
 4+                  >250 cells 
3+                  101 – 250 
 2+                                      51 – 100 
 1+                                        21 – 50 
 Trace                                    2 – 20 
 0                                            0 – 1 
The presence of vitreous cells or opacities was considered necessary 
to make the diagnosis of active pars planitis, and to be included in the study. 
  Fundus examination was done by dilating the pupil with tropicamide 
and 10% phenylephrine. Detailed fundus examination nincluded direct 
ophthalmoscopy, indirect ophthalmoscopy and confirmation of the 
diagnosis by Goldmann 3 mirror examination and the site of abnormalities 
carefully noted. The findings were confirmed independently by a uveitis 
specialist. 
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Vitreous opacities were graded as by Nussenblatt`s classification as
 GRADE                  DESCRIPTION   
    0                          Clear vitreous   
    1+                        Few scattered opacities,  Fundus view unimpaired  
              2+                        Moderate vitreous opacities, Fundus view 
 somewhat impaired 
              3+                        Many opacities, marked blurring of fundus  
 details 
              4+                        Dense opacities. No fundus view 
                
The location of whitish gray snow ball opacities in the peripheral 
retina was noted. Exudates characteristically present as snow banking was 
considered Hallmark of the disease. The site and extent of the snow banking 
was noted.The character of the retinal vessels both in periphery and inthe 
posterior pole was observed by indirect ophthalmoscopy and 3 mirror 
examination. Para venous edema and periphlebitis and vasculitis were 
localized. Macular changes were looked for, and early and suspected 
macular edema was subjected to fundus fluorescein angiography, Goldmann 
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3 mirror examination was done to look for macular hole and epiretinal 
membrane formation. 
                     A detailed and careful examination of the fundus was done to 
rule out any retinochoroiditis. Active and multifocal retinochoroiditis was 
considered to be posterior uveitis with intermediate spill-over and were 
excluded from the study. Patients with peripheral few retinochoroiditis were 
not excluded from the study. 
                       Patient’s visual acuity was measured by Snellen`s charts and 
refraction with improvement of vision with glasses were recorded at the 
time of inclusion into the study. The patients’ visual acuity was followed up 
at the periodic review of the patient.  
Amsler grid was examined at the time of inclusion. Patients were 
followed up for alteration in the image size and shape at every periodic 
review. Pupillary reflex was carefully noted and swinging flash light done to 
exclude optic neuritis. 
  Presence of complications like peripheral anterior synechiae, 
posterior synechiae, glaucoma, posterior capsular cataract was looked for. 
         Macular degeneration was looked for presence of retinal detachment, 
vitreous haemorrhage were examined. 
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INVESTIGATIONS 
 Routine investigations were done on all patients. They included total, 
differential count, urine analysis, serum VDRL and chest X-ray. Mantoux 
was done on all patients to rule out tuberculosis and to get the baseline 
before the patients were put on steroids. Anergy to PPD was also looked for 
along with the clinical examination and chest X-ray to rule out sarcoidosis. 
Patients who had a positive mantoux test were referred to TB clinic 
forruling out primary pulmonarytuberculosis. 
Associated Rheumatological disorders were ruled out by looking for 
rheumatoid factor on patients who were suspected to have clinical 
symptoms and signs of collagen vascular disease. 
Fluorescein Angiography was done mainly 
1. To assess the presence and extent of cystoid macular edema in         
suspected eyes. 
2. To examine the retinal vasculature for signs of perivasculitis which 
included staining of vessel wall and vascular leakage of dye. 
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Cystoid macular edema was classified as 
a. Mild  : with increase thickness of macula 
: decrease in size of Foveal Avascular Zone 
b. Moderate :  Pooling of dye in paramacular region. It is often  
associated with late leakage 
c. Severe      :  Flower petal pattern due to leakage of dye from the 
         perifoveal capillaries. 
OCT was done in four patients with clinical evidence of CME. 
TREATMENT AND FOLLOW UP 
                   After detailed examination of the patients and recording of 
findings, and result of investigations, and opinion from dental, 
otolaryngology and rheumatology for ruling out focal sepsis and collagen 
vascular disease, the patients were categorized for medication. 
TREATMENT PROTOCOL 
Patients observed : 
a. Vision of more than 6/12 
b. Absence of CME 
 
 
  45
c. Absence of confluent exudates or vasculitis 
d. Symptoms which did not hinder their routine daily activities,  
     provided they were not started on steroids from the referral units. 
Patients started on Posterior Subtenon Dexamethasone 
a.  Presence of definite CME 
b. Vision of less than or equal to 6/12 
c.  Patients who had bilateral disease, but were willing for daily injection 
d.  Patients who had vision of more than 6/12, but had symptoms like 
floaters, haziness of vision which hampered their daily activities. 
Patients started on systemic steroids 
a.  Eyes with severe CME 
b. Bilateral signs of pars planitis 
c.  Patients not responding to subtenons for 2 weeks or worsening during 
treatment or not showing compliance for posterior subtenon 
injections. 
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d.  Confluent pars plana exudates and vitreous opacities causing  
defective vision. 
Patients started on Immunosuppressives 
a.  Not responsive to oral and subtenon`s steroids for 2 weeks 
b.  Not tolerant to steroids. 
Patients who had cryopexy 
a.  Were not regular for follow up. 
b.  Had confluent snow banking and vasculitis. 
c.  Not responsive to oral and subtenon`s steroids for 2 weeks and not 
tolerant or fit for immunomodulators and for worsening on treatment 
without a vitreous haemorrhage. 
Treatment was indicated when 
1.  Visual acuity was 6/12 or less. 
2.  Patients with presence of CME and 
3.  Patients with extensive pars plana exudates and vitreous opacity, who 
were symptomatic even though the visual acuity was maintained.  
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Most of these patients presented with hazy vision, and floaters which 
prevented them from doing their routine activities were considered for 
treatment if their complaints did not improve after 2 weeks on 
placebo treatment. 
4.  Patients who were classified as exudative type of pars planitis and 
vasoproliferative type of pars planitis were considered for more 
radical treatment which included systemic steroids and Cryotherapy. 
5.  Patients who developed complications like glaucoma, while on 
steroids were considered for cryotherapy. 
6.  Patients who had anterior segment inflammation which included cells 
in anterior chamber and fresh KP`s were started on treatment of 
anterior uveitis with topical steroids and patients were Atropinised to 
prevent complication of anterior uveitis. 
7.  Treatment for cataracts, with pars planitis were considered when the 
gross decrease in vision was due to the lens opacity  
 Once the patients were decided to be started on therapy, with steroid, 
routine mantoux, blood sugar 2 hours post prandial and IOP were noted. 
Those who had unilateral disease, or predominantly unilateral disease, 
mostly of the serous and infiltrative type were started on posterior 
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subtenon`s injection of Dexamethasone by Nussenblatt`s method in the 
superotemporal quadrant alternate days for 2 weeks. The findings were 
reviewed after 2 weeks. Subjective improvement of quantity of visionwas 
also sought for. Exudative type of pars planitis was also similarly given a 
therapeutic trial with subtenon injection of dexamethasone of 4mg alternate 
days for 2 weeks. 
Patients who had equivocal macular edema and clinical findings not 
consistent with the loss of vision and subjective symptoms were subjected to 
fundus fluorescein angiography by the zeiss camera and further peripheral 
leaks were noted. 
Those patients who had not responded to posterior subtenons steroids 
were started on systemic steroids. Patients who had also visual acuity less 
than 6/12 even after subtenons injection of steroids after 2 weeks were 
considered for systemic steroids. Patients who had bilateral disease were 
considered for systemic steroids especially when they had CME. Patients 
who were not cooperative for subtenon injection and were willing to come 
on atleast fortnightly follow up were also put on systemic steroids. 
   Tablet prednisolone was given at 1mg/kg/day in a single dose. This 
was continued for 1 week and improvement of visual acuity and subjective 
symptoms were asked for. Clinical examination was also done to correlate 
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the complaints. Severe inflammation and CME with gross reduction of 
vision were put on 1.5mg/kg/day of prednisolone. 
The patient was reassessed after 2 weeks and those patients who had 
improved visual acuity, complaints and clinical findings were considered for 
tapering of steroids. 
 Those patients who did not respond to steroids even after 2 weeks 
were considered for immunosuppressives. Patients who were not willing or 
not tolerant to immunosuppressives were subjected to Cryotherapy. 
Cryotherapy was considered for patients with extensive exudative 
disease and vasoproliferative type of pars planitis. Modified Aaberg`s 
method of Cryotherapy was done without peritomy. Areas of extensive pars 
plana exudate was treated with freeze thaw freeze technique. Areas of 
abnormal vasculature were treated, most of which were associated with 
exudates. Patients, who were on systemic steroids, were continued at same 
dose for 1 week. The patient’s visual acuity and subjective response was 
asked for on review after 1 week and decision to taper the steroids or 
continue them was taken. If there was deterioration of visual acuity of more 
than 2 lines, patients were started on steroids. Further examination was done 
after 1 month. 
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Patients were followed up on maintenance dose of steroids and on 
observation once every month for possible complications and exacerbation 
of disease. Remainders were sent once in 4 months for those patients who 
did not come for follow up. 
Patients who needed cataract surgery were taken up for 
phacoemulsification with PCIOL under cover of systemic and subtenon 
dexamethasone 2 days before surgery with subtenon on the day of surgery. 
Patients were also started on T.prednisolone at 0.5mg/kg/day. Patients were 
followed up once a day for 4 days and subsequently once a week for 
development of pars planitis for one month.  
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AGE  AND  INC IDE NC E
8%
10%
20%
26%
16%
16%
4%
   10‐15
16‐20
21‐25
26‐30
31‐35
36‐40
>40
RESULTS AND ANALYSIS 
A. DEMOGRAPHY AND SYMPTOMS 
Total no. of cases included in study: 50 patients 
I. AGE : INCIDENCE 
YEARS NO. OF CASES PERCENTAGE 
10-15 4 8 
16-20 5 10 
21-25 10 20 
26-30 13 26 
31-35 2 4 
36-40 8 16 
>40 8 16 
 
 
 
 
 
46% of patients were between the age groups of 20-30 years. 
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SEX AND PERCENTAGE
44%
56%
MALE
FEMALE
II. SEX 
SEX NO. OF CASES PERCENTAGE 
MALE 28 56 
FEMALE 22 44 
 
 
 
 
 
 
 
 
 
There was no sex predilection. Percentages were 56 male patients and 44 
female patients. 
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III. LATERALITY 
 
 
 
 
 
 
 
LATERALITY OF 
SIGNS 
NO. OF CASES PERCENTAGE 
UNILATERAL 26 52 
BILATERAL 24 48 
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LATERALITY OF SYMPTOMS AND 
PERCENTAGE
40%
60%
UNILATERAL
BILATERAL
 
 
 
 
 
 
 
60% of patients came with unilateral symptoms. 48% of patients had 
signs of bilateral disease. Total no. of eyes affected was 74. 
 
 
 
LATERALITY OF   
SYMPTOMS 
NO. OF CASES PERCENTAGE 
UNILATERAL 30 60 
BILATERAL 20 40 
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IV. ASSOCIATED DISORDERS 
S. No ASSOCIATED DISORDERS NO. OF CASES 
1 HEALED CHORIORETINITIS 6 
2 HIGH MYOPIA 2 
3 PRIMARY COMPLEX 1 
 
B. SIGNS  
I. a. ANTERIOR SEGMENT INVOLVEMENT 
SIGNS NO. OF EYES 
KP`S 18 
FLARE` 25 
CELLS 19 
25 out of 74 eyes had signs of anterior segment spill over. All thepatients 
with anterior segment signs had mild degree of flare. KP`s were present in 
24% of patients with pars planitis. 26% of patients had cells in anterior 
chamber. 
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TYPES AND PERCENTAGE
32%
45%
5%
18%
Ia
Ib
II
III
b. TYPE OF PARS PLANITIS (BOKE`S CLASSIFICATION WITH 
SLOVAK MODIFICATION) 
TYPE NO. OF EYES % n = 74 
Ia 33 44.6 
Ib 24 32.4 
II 13 17.6 
III 4 5.4 
 
 
 
 
 
 
 
77% of the eyes involved belonged to the diffuse inflammatory type (typeI). 
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II. CLINICAL PRESENTATION  
PATIENT  
COMPLAINTS 
NO. OF EYES PERCENTAGE 
FLOATERS 33 45% 
VISUAL LOSS 36 49% 
HAZY VISION 43 58% 
SYMPTOMS OF 
ANTERIOR UVEITIS 
40 54% 
 
 
 
 
 
 
Haziness of vision was the chief complaint in 58% of patients.54% of 
them had symptoms of anterior uveitis like redness, photophobia and 
watering. 
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III. CORRELATION WITH TYPE AND ANTERIOR SEGMENT 
INVOLVEMENT 
TYPE NO. OF EYES 
EYES WITH  
ANTERIOR 
SEGMENT 
INVOLVEMENT 
PERCENTAGE 
Ia 33 7 21% 
Ib 24 6 25% 
II 13 8 62% 
III 4 4 100% 
 
 
 
 
 
 
 
More than half of the eyes with exudative type had anterior segment spill 
over. All cases of type III had spill over anterior uveitis. 
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IV. POSTERIOR SEGMENT INVOLVEMENT 
A.CORRELATION BETWEEN VITREOUS CELLS AND VISUAL 
ACUITY AT PRESENTATION 
VITREOUS 
CELLS 
VISION  AT  PRESENTATION 
6/6-6/9 6/12-6/18 6/24-6/36 6/60 & > TOTAL 
0 27 2 4 0 33 
1+ 3 5 5 3 16 
2+ 1 11 9 17 38 
3+ 0 2 3 7 12 
4+ 0 0 0 0 0 
 
Eyes with visual loss of more than 6/24 on snellen`s chart were more 
likelyto have vitreous cells. The loss of vision is directly proportional to 
theintensity of inflammation of vitreous.  
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B. VITREOUS OPACITY AND VISUAL ACUITY AT      
PRESENTATION 
VITREOUS  
OPACITY 
                    VISION  AT  PRESENTATION 
6/6-6/9 6/12-6/18 6/24-6/36 6/60&> TOTAL 
0 22 3 2 0 27 
1+ 6 7 7 14 34 
2+ 3 9 11 8 31 
3+ 0 1 1 2 4 
4+ 0 0 0 2 2 
34% of patients had vitreous opacities of 1+. Eyes with vitreous opacities of 
4+ at presentation had considerable loss in visual acuity. No direct 
correlation was found between the visual loss and amount of vitreous 
opacities. 
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SNOWBALL OPACITIES & PERCENTAGE
40%
37%
12%
11% UN
UT
LN
LT
C. SITE OF SNOWBALL OPACITIES 
SITE OF SNOW BALL NO. OF EYES 
UN 12 
UT 11 
LN 40 
LT 37 
   
 
 
 
 
 
 
Snow ball opacities are more common in the inferior half of the vitreous. 
40% of eyes had involvement of the lower nasal quadrant.  
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36%
UT
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UN
7%
LT
50%
D. SITE OF SNOW BANKING 
SITE OF SNOW BANKING NO. OF EYES 
UN 3 
UT 3 
LN 16 
LT 22 
 
 
 
 
 
 
 
50% of eyes with snow banking had it in the lower temporal 
quadrant. 86% of the snow banking was in the lower half of retina. 
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E. CORRELATION BETWEEN EXTENT OF SNOWBANKING AND 
VISUAL LOSS 
NO. OF 
QUADRANTS 
INVOLVED 
6/6-6/9 6/12-6/18 6/24-6/36 6/60&> T 
1Q 1 2 2 3  
2Q - 1 4 7 12 
3Q - - 1 1 2 
4Q - - 1 - 1 
 
Snow banking was present in 23 eyes with pars planitis. Eyes with 
more than 2 quadrant of snow banking had considerable visual loss.  
 
 
 
 
 
 
 
 
  64
LT
27%
LN
27%
UT
24%
UN
22%
 
F. SITE OF PERIVASCULITIS 
SITE OF PERIVASCULITIS NO. OF EYES 
UN 8 
UT 9 
LN 10 
LT 10 
 
   
 
 
 
 
 
Lower half of retina had 54% of the vasculitis. But there was no 
direct correlation between vasculitis and snow banking  even though most of 
the vasculitic vessels had snow banking near them. 
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G. EXTENT OF VASCULITIS AND THEIR CORRELATION WITH 
REDUCTION IN VISUAL ACUITY 
EXTENT 6/6-6/9 6/12-6/18 6/24-6/36 6/60&> T 
1Q 4 1 2 - 7 
2Q - 2 1 2 5 
`3Q - 1 2 - 3 
4Q - - - 3 3 
 
Gross reduction of vision was seen in patients with all 4 quadrants 
with vasculitis. More than 50% of patients with one quadrant of vasculitis 
had good visual acuity. 
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H. VISUAL LOSS WITH CLINICAL EVIDENCE OF CYSTOID 
MACULAR OEDEMA 
SEVERITY 
OF CME 6/6-6/9 6/12-6/18 6/24-6/36 6/60&> T 
MILD 1 5 10 6 22 
MODERATE - 1 - 1 2 
SEVERE - - - 1 1 
 
25 eyes had evidence of CME (34%) out of 74 eyes with pars planitis. 
88% of patients had mild CME. Moderate CME was associated with gross 
reduction in visual acuity.  
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S E VE R ITY  OF  CME  AND  
PE RC E NTAGE
88%
8%
4%
MILD
MODE RATE
S E VE RE
I. FUNDUS FLUORESCEIN ANGIOGRAPHY 
SEVERITY OF CME NO. OF EYES 
MILD 21 
MODERATE 2 
SEVERE 1 
 
 
 
 
 
 
 
 
 
 
 
88% of eyes had mild form of CME.  
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III
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J.TYPE OF PARS PLANITIS AND THEIR SIGNIFICANCE ON 
VISUAL ACUITY 
TYPE 6/6-6/9 6/12-6/18 6/24-6/36 6/60&> T 
Ia 7 14 6 6 33 
Ib 2 1 8 13 24 
II - 3 5 5 13 
III - 1 1 2 4 
 
 
 
 
 
 
 
 
Type Ib, type II and type III ie.,infitrative, exudative and vasculitic 
type of pars planitis had gross defective vision (less than 6/18). While in 
serous type 21% had normal visual acuity. 
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V.A. TREATMENT 
Modality of 
Treatment 
Stable Improve 1 
line 
Improve 2 
lines 
Improve 3 or 
more lines 
Deterioration T 
SUBTENONS 
STEROIDS 
1 4 6 4 - 15
SYSTEMIC 
STEROID WITH 
POSTERIOR 
SUBTENONS 
 
7 
 
12 
 
14 
 
20 
 
- 
 
53
 
IMMUNOSUPP
RESSIVE 
 
- 
 
1 
 
1 
 
1 
 
- 
 
3 
WITH 
CRYOPEXY 
- 1 3 1 - 5 
OBSERVATION 
ONLY 
- 1 2 - - 3 
TOTAL 8 19 24 26 - 79
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Most of our patients (67%) were treated with systemic and subtenon 
steroids. 90% of patients had improvement of visual acuity on treatment 
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B. SUBJECTIVE IMPROVEMENT OF SYMPTOMS 
 Ia Ib II III TOTAL 
WORSENING 1 1 4 - 6 
STATIC 3 5 2 1 11 
IMPROVED 30 15 6 3 54 
 
C. COMPLICATIONS 
COMPLICATIONS NO. OF PATIENTS 
RAISED INTRAOCULAR 
PRESSURE 3 
VITREOUS HAEMORRHAGE 1 
POSTERIOR SUBCAPSULAR 
CATARACT 
 
8 
 
Posterior subcapsular cataract was the most common complication 
noted.Out of 8 patients, 3 patients underwent phacoemulsification with 
PCIOL implantation after observation of quiescence of eye for 3 months 
during the follow up period. 
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DISCUSSION 
In our study of 50 patients (74 eyes) with pars planitis it was observed that 
30% of patients were in the age group of 15-25 years and 32% of patients in 
fourth and fifth decade. This shows the bimodal age distribution with peaks 
in second and fifth decade. 
Fourty four percentages of patients were females. There was no sex 
predilection as reported in other studies as well. (Nussenblatt uveitis, 
fundamentals and clinical practice). 
Fifty two percent of patients had unilateral signs of pars planitis. This 
did not correlate with studies done by Kimura which showed 71% being 
bilateral and 75% bilaterality reported by Stewart Duke Elder. 
Aaberg had noticed minimal anterior segment inflammation in many 
of his patients, 34% of our patients had minimal anterior segment signs. But 
none of our patients had either peripheral anterior synechiae, or posterior 
synechiae as reported by Brockhurst in 24 and 18 percent ofhis patients 
respectively. 3 patients had increased intraocular pressure and there were no 
patients who had glaucoma. But Kimura reported that 8% of his 182 eyes 
developed glaucoma of which 67% of them were related to corticosteroid 
use and only 2% had disease induced glaucoma.      
 
 
  73
Boke`s classification modified by Slovak was used to classify pars 
planitis because it was a purely clinical method of classification. There has 
been no reported study which has correlated the clinical presentation based 
on classification by Boke. Smith in 1977 had reported 43% with mild, 46% 
with moderate severity of pars planitis while he had 11% who had severe 
type of pars planitis. Our study showed that 77% had diffuse inflammatory 
type of which 44.6% were of the serous type and 32.4% had infiltration type 
of pars planitis. The most severe vasculitic type was present in only 5.4% of 
our patients. Gross defective vision was present in 77% of patients with type 
II (exudative type) and 75% of patients with type III (vasoproliferative) pars 
planitis. 
Brockhurst had noted that snow banking and snow ball opacities 
wasmostly located inferiorly. It was true in our study where 86% and 77% 
ofpatients had inferior location of snow banking and snow ball opacities.  
There was no direct correlation between the presence of vitreous 
celland vitreous opacities with visual loss in our patients, even though only  
17% of patients with vitreous cells of 3+ and 25% of patients with vitreous 
opacities of 3+ had normal visual acuity. 67% of patients with moderate 
CME were associated with gross defective vision (Aaberg, TM., The 
Enigma of Pars planitis Am.J.Ophthal 103: 828-830, 1987).  
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Schlaegel had found that 67% of eyes treated with corticosteroids 
maintain visual acuity of more than 6/12. 67% of our patients responded to 
subtenons steroids while 64% of the patients responded to addition of 
systemic steroids along with subtenon`s injection of steroids. In our study, 
out of 50 patients, 5 patients underwent Cryotherapy. Visual acuity 
improvement was seen in 80% of the patients who were subjected to 
Cryotherapy. This correlates well with the study by Devenyi in which he 
reported elimination of vitritis with improvement in visual acuity in 78% of 
cases.  
Cataract extraction by phacoemulsification with posterior chamber 
intraocular lens implantation was done in 3 of our patients after 3 months of 
quiescence of the eye. Two out of three patients had more than 6/12 visual 
acuity post operatively. Michelson has reported 51% of eyes with more than 
6/12 vision after cataract surgery. Sudha.k.ganesh in her study analyzed that 
phacoemulsification with IOL implantation in eyes with pars planitis was 
safe and led to good visual outcomes in most cases. The factors in surgical 
success were control of inflammation, meticulous surgery, in-the-bag IOL 
implantation, and vigilant postoperative care.     
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CONCLUSION 
1.  The demographic pattern of our pars planitis compares well with the 
other studies with the bimodal age distribution with peaks in second 
and fifth decade and with no sex predilection.  
2.  Though the commonest type of pars planitis is serous or infiltrative 
type (Type Ia&Ib), Patients who belonged to BOKE`s classification 
Type II and Type III ie., exudative and vasculitic type had a more 
severe form of pars planitis and requires early aggressive treatment. 
3.  Fundus fluorescein angiography was required to ascertain whether the 
patient had CME. It not only picks up early CME, but also helps 
inidentifying patients who will develop more aggressive disease. 
Optical Coherence Tomography has become a better tool to diagnose 
and follow up patients with CME.  
4.  Severity of vitreous cells, extent of snow banking and CME are 
prognostic indicators. Patients with increased amount of vitreous 
cells, with more than 3 quadrant of snow banking and with moderate 
CME warrant intensive treatment. 
5.  There is a high incidence of snow banking in the inferior half of 
retina, gravity being a determinant as comparable with other studies. 
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6. Treatment with a combination of systemic with subtenon`s 
administration of steroids gives good visual outcome for patients with 
pars planitis. Patients refractory to this line of management responds 
well to immunomodulators and Cryotherapy. 
7.   Cataract extraction on a quiescent eye under cover of steroids helps in 
visual rehabilitation of patients who develop significant loss of visual 
acuity due to the same.   
 
 
 
 
  
 
 
 
 
 
PART III 
PROFORMA 
A MULTIFACTORIAL ANALYSIS OF 50 CASES OF PARS PLANITIS 
 
NAME:       ADDRESS: 
AGE: 
SEX: 
SYMPTOMS 
      UNILATERAL  BILATERAL 
             RE        LE 
I. Laterality 
      Duration 
II. Defective vision 
     Hazy vision 
      Signs of anterior uveitis 
      Pain 
      Redness 
     Watering 
    Photophobia 
III. History suggestive of 
        Rheumatological disorder 
       Collagen vascular disease 
       Vasculitic disorder 
       Infective: Tuberculosis 
                          Others 
       Demyelinating diseases 
       Focal sepsis: ENT, Dental, Gynac (in females) 
       Pets 
       Diet 
IV. Previous Episode 
       Age at onset 
       No. of episodes 
      Response to treatment 
V. History of 
      Diabetes 
      Hypertension 
      Smoking 
      Alcohol intake 
      Exposure to pulmonary tuberculosis patient 
VI. Family history of similar illness 
 
 
 
SIGNS 
1. Laterality   Unilateral                 Bilateral 
                                                   RE     LE 
                                        At onset/On review  At onset/On review 
2. Anterior segment spillover 
a. Circumciliary congestion 
b. Keratic precipitates (1+, 2+, 3+, 4+) 
c. Flare (0, ±, 1+, 2+, 3+, 4+) 
d. Cells (0, ±, 1+, 2+, 3+, 4+) 
3. Intermediate Uveitis 
a. Vitreous cells (0, ±, 1+, 2+, 3+, 4+) 
b. Vitreous opacity (0, ±, 1+, 2+, 3+, 4+) 
c. Snow ball opacity (UN LN LT UT) 
d. snow banking (UN LN LT UT) 
e. Pars plana vascularization (UN LN LT UT) 
f. Retinal periphlebitis (UN LN LT UT) 
g. Vitreous haemorrhage 
h. Retinal detachment 
i.  Cystoid macular edema No 
                                          Yes- mild/moderate/severe 
4. Presence of complications- at onset/on review 
a. Peripheral anterior synechiae 
b. Posterior synechiae 
c. Glaucoma 
d. Complicated cataracts 
e. Macular degeneration 
5. Presence of optic neuritis  
a. Visual acuity 
b. Visual fields 
c. Relative afferent pupillary defect 
d. Colour vision 
e. ONH swelling 
f. Amslers grid 
DIAGNOSTIC TYPE 
1. Diffuse inflammatory     a. Serous 
                                            b. Infiltrative 
2. Exudative 
3. Vasoproliferative 
 
INVESTIGATIONS 
1. Total blood count 
2. ESR 
3. Mantoux 
4. VDRL 
5. Rheumatoid factor 
6. TORCH screening 
7. Antinuclear antibody 
8. Chest X-ray 
FUNDUS FLUORESCEIN ANGIOGRAPHY 
Normal 
Abnormal: 
Disc 
Presence of vasculitis 
Cystoid macular edema- mild/moderate/severe 
Others: 
TREATMENT 
1. Posterior subtenon`s steroids: +/- 
2. Systemic steroids: +/- 
3. Immunosuppressives: +/- 
4. Cryotherapy: 
a. Quadrants covered (UN LN LT UT) 
b. Visual acuity at 1 week, 2 weeks, 1 month                             
                                  
OUTCOME 
a. Visual outcome 
b. Amsler`s grid 
c. Subjective response- static/improve/worsen 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 ABBREVIATIONS 
M       MALE 
F        FEMALE 
RE      RIGHT EYE 
LE      LEFT EYE 
UL      UNILATERAL 
BL       BILATERAL 
R          REDNESS 
Ph         PHOTOPHOBIA 
W         WATERING 
P           PAIN 
CT        CARIES TOOTH 
CR        CHORIORETINITIS 
HM       HIGH MYOPIA 
Pt          PTHYSIS 
PC        PRIMARY COMPLEX 
KP        KERATIC PRECIPITATE     
UT       UPPER TEMPORAL   
UN     UPPER NASAL 
LT     LOWER TEMPORAL 
LN     LOWER NASAL 
CME     CYSTOID MACULAR EDEMA 
PVD       POSTERIOR VITREOUS  DETACHMENT          
ERM      EPIRETINAL MEMBRANE 
DE          DISC EDEMA 
HMD      HYPEREMIA OF DISC         
Mi        MILD  
Mo           MODERATE 
Se  SEVERE 
FFA  FUNDUS FLUORESCEIN ANGIOGRAPHY 
C V/A-Ad CORRECTED VISUAL ACUITY AT THE TIME OF  
   ADMISSION 
PSCC     POSTERIOR SUBCAPSULAR CATARACT 
IOP         INTRAOCULAR PRESSURE 
VitHmg VITREOUS HAEMORRHAGE 
HM           HIGH MYOPIA 
O              OBSERVATION 
S/T S        SUBTENONS STEROIDS 
SS            SYSTEMIC STEROIDS 
IS             IMMUNOSUPPRESSIVES 
CRYO      CRYOTHERAPY 
V/A EF     VISUAL ACUITY AT THE END OF FOLLOW UP 
N               NORMAL 
MH           MILD HAZINESS 
St               STABLE 
MoH          MODERATE HAZINESS 
HV             HAZY VISION 
 
  LIST OF SURGERIES PERFORMED 
1 SUNDARI 35 F 652301 RE-CHALAZION RE-INCISION AND CURETTAGE 
2 SELVI 26 F 281766 RE-PTERYGIUM RE-PTERYGIUM EXCISION WITH AUTOGRAFT 
3 RAJAN 45 M 622091 LE-PANOPHTHALMITIS LE-EVISCERATION 
4 VELU 68 M 521907 RE-CHRONIC DACRYOCYSTITIS RE-DACRYOCYSTECTOMY 
5 PONNAMMAL 42 F 646111 LE-CHRONIC DACRYOCYSTITIS LE-DACRYOCYSTORHINOSTOMY 
6 MOORTHY 34 M 523012 LE-TRAUMATIC ENDOPHTHALMITIS LE-INTRAVITREAL CEFTAZIDIME AND VANCOMYCIN 
7 RAMESH 20 M 644432 RE-TRICHIASIS RE-EPILATION 
8 MUNIAMMA 63 F 679438 RE-ABSOLUTE GLAUCOMA RE-CYCLOCRYOTHERAPY 
9 CHELLAM 57 M 612406 RE-UPPER LID LACERATION RE-SUTURING OF UPPER LID 
10 RAMASAMY 70 M 676450 RE-PROPTOSIS WITH EXPOSURE RE-CENTRAL TARSORRHAPHY 
11 BALAMMA 43 F 633218 LE-CHRONIC DACRYOCYSTITIS LE-DACRYOCYSTORHINOSTOMY 
12 GOVINDARAJ 55 M 679032 
LE-POSTOPERATIVE 
ENDOPHTHALMITIS 
LE-INTRAVITREAL CEFTAZIDIME AND VANCOMYCIN 
13 VELANKANNI 62 F 632456 RE-MATURE CATARACT RE-ECCE WITH PCIOL 
14 RAJESHWARI 55 F 680933 LE-IMMATURE CATARACT LE-SICS WITH PCIOL 
15 RAMANI 58 M 600092 RE-MATURE CATARACT RE-ECCE WITH PCIOL 
16 BASHA 23 M 657490 LE-PTERYGIUM LE-PTERYGIUM EXCISION WITH AMNIOTIC MEMBRANE GRAFT 
17 KANMANI 56 F 612900 RE-MATURE CATARACT RE-SICS WITH PCIOL 
18 NITHYANANDAM 13 M 654739 LE-CHALAZION LE-INCISION AND CURETTAGE 
19 RAMACHANDRAN 68 M 699435 RE-MATURE CATARACT RE-ECCE WITH PCIOL 
20 SELVAM 72 M 621213 LE-IMMATURE CATARACT LE-SICS WITH PCIOL 
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FUNDUS PICTURE OF A PATIENT SHOWING VITRITIS 
FUNDUS PICTURE SHOWS SNOWBALL OPACITIES 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FUNDUS PICTURE OF A PATIENT WITH SNOWBANKING
 
 
VASCULAR SHEATHING SEEN IN A CASE OF PARSPLANITIS WITH VASCULITIS
FLUORESCEIN ANGIOGRAM SHOWING LATE STAINING OF VESSEL IN A 
PATIENT OF PARS PLANITIS WITH VASCULITIS 
 FUNDUS PICTURE OF A PATIENT WITH BILATERAL CME 
 FLUORESCEIN ANGIOGRAM OF A PATIENT WITH MILD CME – DECREASE IN 
FOVEAL AVASCULAR ZONE
FLUORESCEIN ANGIOGRAM OF A PATIENT WITH MODERATE CME
 FLUORESCEIN ANGIOGRAM OF A PATIENT WITH SEVERE CME FLOWER  
PETAL PATTERN
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
OCT SHOWS CYSTOID MACULAR EDEMA WITH CENTRAL MACULAR 
THICKNESS OF 634μ 
RE LE RE LE RE LE KP s CELLS FLARE KPs CELLS
1 MANIKANDAN 17 M UL ‐ ‐ ‐ ‐ ‐  +     R,P,Ph(LE) UL      ‐      ‐      ‐ 1      ‐      ‐
2  SELVARANI 28 F UL  +  ‐  ‐  ‐   +   + Ph (RE)  ‐ BL    ‐       ‐   ‐ 2   ‐    ‐
3 MALLIKA 24 F BL  ‐  ‐  +  +  ‐  ‐ CCC (BE)  ‐ BL  +  ‐  ‐ 3  + 2+
4 PRABAKARAN 13 M UL  ‐  ‐  ‐  ‐  ‐  + Ph(LE)  ‐ UL  ‐  ‐  ‐ 4   ‐   ‐
5 CHANDRAN 47 M BL  +  +  +  +  ‐  ‐  R (BE)  CT  BL  ‐  ‐  ‐ 5  ‐  ‐
6 DHAMODARAN 28 M UL  ‐  ‐  ‐  +  ‐  ‐  ‐  ‐   UL   ‐  ‐  ‐ 6  ‐  1+
7 SELVARAJ 14 M UL  ‐   ‐    +  ‐   ‐  ‐   ‐  ‐ UL  ‐  ‐  ‐ 7  ‐  ‐
8 PARTHIBAN 35 M UL  ‐  +   ‐   +  ‐  +  Ph(LE)  ‐  UL   ‐  ‐  ‐ 8  ‐  ‐
9 SIVARANJANI 23 F  UL  ‐  ‐  +  ‐  ‐  ‐  R (RE)  ‐ UL  ‐  ‐  ‐ 9  ‐  ‐
10 MOHAN 45 M BL  ‐  ‐  ‐  ‐  +  +   ‐  ‐   BL  ‐ 1+ 1+ 10  ‐  ‐
11 GEETHA 30 F UL  ‐  ‐  +  ‐  ‐  ‐  ‐   CR (RE) UL  ‐  ‐  ‐ 11  ‐  ‐
12 SELVI 20 F UL  ‐  ‐  ‐  +  ‐  ‐  ‐  ‐  UL  ‐  ‐  ‐ 12  ‐  ‐
13 JEEVA 50 F BL  +  +  +  +  ‐  ‐ Ph(BE) CR (RE) BL  ‐ 1+ 2+ 13  ‐ 1+
14 SANGEETHA 11 F UL  ‐  ‐  ‐  ‐  +  ‐ R,Ph(RE) Asthmatic UL  ‐  ‐  ‐ 14  ‐  ‐
15 SARASWATHY 43 F BL   +  + + + ‐ ‐ P,W(BE)  ‐ BL + 1+ 1+ 15 ‐ ‐
16 KEERTHANA 8 F UL ‐ ‐ ‐ + ‐ + Ph(LE) CR(LE) UL  ‐  ‐  ‐ 16  ‐  ‐
17 SRIKUMARAN 28 M UL ‐ ‐ ‐ ‐ ‐  +     R,P,Ph(LE)  ‐ UL      ‐      ‐      ‐ 17      ‐      ‐
18 KARTHICK 30 M UL + ‐ + ‐ + ‐ ‐ ‐ UL ‐ ‐ ‐ 18 ‐ ‐
19 RAVI 37 M BL + ‐  +  + ‐ ‐ ‐ ‐ BL  ‐ ‐ ‐ 19 ‐ ‐
20 MEENAKSHI 50 F BL  +  +  ‐  ‐  +  +  ‐   CR (RE) BL  ‐  ‐  ‐ 20  ‐  ‐
21 MANI 40 M UL  ‐  ‐  +  ‐  + ‐ ‐   ‐ UL ‐ ‐ ‐ 21 ‐ ‐
22 PARAMASIVAN 28 M BL  + +  + + ‐ ‐ R(BE) ‐ BL ‐ ‐ ‐ 22  + ‐
23 SAMPATH 45 M BL  +  +  ‐  ‐  +   + Ph(BE) HM(BE) BL  ‐  ‐  ‐ 23  + 1+
24 SARAVANAMOORTHY 36 M BL  +  +  ‐  ‐  +  +  ‐  ‐ BL  + 1+ 1+ 24  + 1+
25 RAVUTHAR 22 M UL ‐ ‐ ‐ ‐ ‐ + P,R(LE) ‐ UL ‐ ‐ ‐ 25 + ‐
26 KUMAR 30 M UL + ‐ ‐ ‐  + ‐ Ph(RE) ‐ UL ‐ 1+ 1+ 26 ‐ ‐
27 SHANTHI 40 F BL ‐ ‐ ‐ ‐ + + ‐ CR(RE) BL ‐  ‐  ‐ 27  ‐  ‐
28 JAYANTHI 24 F UL  ‐  ‐  ‐   ‐  ‐  + P,W(LE) CT UL  ‐  ‐  ‐ 28  ‐  ‐
29 JAYA  40 F BL + + +  ‐ + + Ph(BE) HM(BE) BL  ‐  1+ 1+ 29  ‐ 1+
30 MANIMARAN 30 M UL  +  ‐  ‐  ‐  +  ‐  ‐  ‐ UL  ‐  ‐  ‐ 30  ‐  ‐
31 VINOTH 22 M UL  ‐  ‐  +  ‐  +  ‐ R(RE) CT UL  + 2+ 2+ 31  ‐  ‐
32 SUJATHA 30 F BL  ‐  ‐  ‐  ‐  +  + R,Ph(BE)  ‐ BL  +  1+  1+ 32  +  1+
33 ARUNACHALAM 42 M BL  + +  + + ‐ ‐ R(BE) ‐ BL ‐ ‐ ‐ 33 ‐ 2+
34 SELVAKUMAR 21 M UL  ‐  ‐  +  ‐  +  ‐ R(RE)  ‐ UL  + 1+ 1+ 34  ‐  ‐
35 ASHOKAN 39 M BL  ‐  ‐  ‐  ‐  +  + R,Ph(BE)  ‐ BL  + 1+ 1+ 35  +  ‐
36 PERUMAL 22 M UL  ‐  +  ‐  ‐  ‐  ‐ R(LE) Pt(RE) UL  ‐  ‐  ‐ 36  ‐ ‐
37 AMSABAI 54 F UL  ‐  ‐  ‐  ‐  +  ‐ R,Ph(RE)  ‐ UL  ‐  ‐  ‐ 37  ‐  ‐
38 SULEKA 38 F UL  ‐  +  ‐  ‐  ‐  + Ph(LE)  ‐ UL  ‐  ‐  ‐ 38  ‐  ‐
39 UDHAYAKUMAR 20 M UL  ‐  ‐  +  ‐  ‐  ‐  R (RE)  ‐ UL  ‐  ‐  ‐ 39  ‐  ‐
40 MADHANKUMAR 28 M UL ‐ ‐ ‐ ‐ ‐  +     R,P,Ph(LE)  ‐ UL      ‐      ‐      ‐ 40      ‐      ‐
41 RAJESH 26 M UL + ‐ + ‐ + ‐ ‐ ‐ UL ‐ ‐ ‐ 41 ‐ ‐
42 NATARAJAN 22 M BL ‐ ‐ + + ‐ ‐ Ph,R(LE) ‐ BL ‐ ‐ ‐ 42 + 1+
43 NAGALAKSHMI 16 F BL ‐ ‐ + + ‐ ‐ ‐ PC BL ‐ ‐ ‐ 43 ‐ ‐
44 ETHIRAJ 30 M UL ‐ ‐ + ‐ + ‐ ‐ CR(RE) UL ‐ ‐ ‐ 44 ‐ ‐
45 LALITHA 23 F BL  +  +  ‐  ‐  +  + ‐ ‐ BL ‐ ‐ + 45 ‐ ‐
46 RANI 26 F UL ‐ + ‐ + ‐ + ‐ ‐ BL ‐ ‐ ‐ 46 ‐ 1+
47 MANOJ 23 M UL ‐ ‐ + ‐ + ‐  ‐ ‐ BL ‐ ‐ ‐ 47 ‐ ‐
48 KAMALA 36 F BL ‐ ‐  ‐  ‐ + + ‐ ‐ BL ‐ ‐ ‐ 48 ‐ ‐
49 VIJAYAKUMARI 20 F BL + + ‐ ‐ ‐ ‐ ‐ CT BL ‐ ‐ ‐ 49  ‐ ‐
50 DEVAKI 33 F UL ‐ + ‐ + ‐ ‐ R(LE) ‐ BL ‐ ‐ ‐ 50 ‐ ‐
MASTER CHART
S.NO.
ANTERIOR SEGMENT ANTERIOR SEGM
                            LE
 ‐
S.NO. NAME AGE  SEX UL/BL
FLOATERS
                                       SYMPTOMS
VISUAL LOSS       HAZY VISION
UL/BL
RE
ANTERIOR UVEITIS ASSO. DISORDERS
FLARE RE LE RE LE UT UN LN LT UT UN LN LT UT UN LN LT UT UN LN LT
     ‐    ‐ 2+   ‐ 2+  ‐  ‐   ‐  ‐  ‐  ‐  +  +   ‐  ‐  ‐  ‐ 1  ‐  ‐  ‐  ‐
  ‐ 3+ 2+ 2+ 2+  ‐  ‐  ‐  ‐  ‐   ‐  ‐  ‐  ‐  ‐  ‐  ‐ 2  ‐  ‐  ‐  ‐
1+  2+ 2+ 1+ 1+  ‐  ‐  ‐  ‐  ‐  ‐  ‐  ‐  ‐  ‐  +  + 3  ‐  ‐  +  +
  ‐   ‐  1+  ‐ 1+  ‐  ‐  ‐  ‐  ‐  ‐  +  +  ‐  ‐  ‐  ‐ 4  ‐  ‐  ‐  ‐
 1+  1+  1+ 1+ 1+   ‐  ‐  ‐   ‐   ‐   ‐   ‐  ‐  ‐  ‐  ‐  + 5  ‐  ‐  ‐  ‐
 1+  ‐  ‐  ‐  ‐  ‐  ‐  ‐  ‐  ‐  ‐  +  ‐  ‐  ‐  ‐  ‐ 6  ‐  ‐  ‐  ‐
 ‐  1+  ‐ 1+  ‐  ‐  +  ‐  ‐  ‐  ‐  ‐  ‐  ‐  ‐  ‐  ‐  7  ‐  ‐   ‐  ‐
 ‐  ‐  2+  ‐ 1+  ‐  ‐  ‐  ‐  ‐  ‐  ‐  ‐  ‐  ‐  ‐  ‐ 8  ‐  ‐  +  +
 ‐  2+  ‐ 2+  ‐  ‐  ‐  +  +  ‐  ‐  ‐  ‐  ‐  ‐  ‐  ‐ 9  ‐  ‐  ‐  ‐
 ‐  3+  3+  2+ 2+  ‐  ‐  ‐  ‐  ‐  ‐  ‐  ‐  ‐  ‐  ‐  ‐ 10  ‐  ‐  +  +
 ‐ 2+  ‐  1+  ‐  ‐  ‐  +  +  ‐  ‐  ‐  ‐  ‐  ‐  ‐  ‐ 11  ‐  ‐  ‐  ‐
 1+  ‐  2+  ‐ 1+  ‐  ‐  ‐  ‐  ‐  ‐  +  +  ‐  ‐  ‐  ‐ 12  ‐  ‐  ‐  ‐
2+ 2+ 2+ 1+ 2+  ‐  ‐  +  +  ‐  ‐  +  +  ‐  ‐  ‐  ‐ 13  ‐  ‐  ‐  ‐
 ‐ 2+  ‐  1+  ‐  ‐  ‐  +  + ‐ ‐ ‐ ‐ ‐ ‐  +  + 14 ‐ ‐ ‐ ‐
‐ 1+ ‐ 1+ 1+  ‐  +  +  ‐  ‐  ‐  +  +  ‐  ‐  ‐  ‐ 15  ‐  ‐  ‐  ‐
1+ ‐ 2+ ‐ 2+  ‐  ‐  ‐  ‐  ‐  ‐  ‐  ‐  ‐  ‐  ‐  ‐ 16  +  ‐  ‐  +
     ‐    ‐ 2+   ‐ 2+  ‐  ‐   ‐  ‐  ‐  ‐  +  +   ‐  ‐  ‐  ‐ 17  ‐  ‐  ‐  ‐
‐ 2+ ‐ 4+ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ 18 ‐ ‐ ‐ ‐
‐ 1+ 1+ 1+ 1+ ‐ ‐  ‐  ‐  ‐  ‐  ‐   ‐  ‐  ‐  +  + 19  ‐ ‐ ‐ ‐
 ‐ 1+ 1+ 1+ 1+  ‐  ‐  ‐  ‐  ‐  ‐  ‐  ‐  ‐  ‐  ‐  ‐ 20  ‐  ‐  +  +
‐ 2+ ‐ 1+  ‐  ‐  ‐  +  ‐  ‐  ‐  ‐  ‐  ‐  ‐  ‐  ‐ 21  ‐  ‐  ‐  ‐
‐ 1+ 2+  1+ 1+ + ‐ + ‐ + + + + ‐ ‐ ‐ ‐ 22 ‐ ‐ ‐ ‐
1+ 2+ 3+ 1+ 2+ ‐  ‐  +  +  ‐  ‐  +  +  ‐  ‐  ‐  + 23  ‐  ‐  +  +
1+ 3+ 2+ 2+ 1+  ‐  ‐  ‐  ‐  ‐  ‐  ‐  ‐  ‐  ‐  ‐  + 24  ‐  ‐  ‐  +
‐ ‐ 1+ ‐ 1+ ‐ ‐  ‐  ‐  ‐  ‐  +  +  ‐  ‐  ‐  ‐ 25  ‐  ‐  ‐  ‐
‐ 2+ ‐ 2+ ‐  ‐  ‐  +  ‐  ‐  ‐  ‐  ‐  ‐  ‐  ‐  ‐ 26  ‐  ‐  ‐  ‐
 ‐  2+  2+ 1+ 2+  ‐  ‐  ‐  ‐  ‐  ‐  +  +  ‐  ‐  ‐  ‐ 27  ‐  ‐  ‐  ‐
 ‐  ‐ 3+  ‐ 2+  ‐ ‐ ‐ ‐ ‐ ‐ ‐  +   ‐   ‐   ‐   ‐ 28   ‐   ‐   ‐   ‐
1+ 2+ 2+ 2+ 1+  ‐  ‐  +  +   ‐  ‐  ‐  +  ‐  ‐  ‐  ‐ 29  ‐  ‐  ‐  ‐
 ‐ 2+  ‐ 1+  ‐  ‐  ‐  ‐  ‐  ‐  ‐  ‐  +  ‐  ‐  ‐  ‐ 30  ‐  ‐  ‐  ‐
 ‐  2+  ‐ 1+ 1+  ‐  ‐  +  +  ‐  ‐  ‐  ‐  ‐  ‐  ‐  ‐ 31  ‐  ‐  ‐  ‐
 1+  3+  3+  1+  2+  ‐  ‐  ‐  ‐  ‐  ‐  ‐  ‐  ‐  ‐  +  ‐ 32  ‐  ‐  ‐  ‐
2+ 1+ 2+  1+ 1+ + ‐ + ‐ + + + + ‐ ‐ ‐ ‐ 33 ‐ ‐ ‐ ‐
 ‐ 1+  ‐ 1+  ‐  ‐  ‐  +  +  ‐  ‐  ‐  ‐  ‐  ‐  ‐  ‐ 34  ‐  ‐  ‐  ‐
 ‐ 1+ 1+ 1+ 1+  ‐  ‐  +  +  ‐  ‐  ‐  +  ‐  ‐  ‐  ‐ 35  ‐  ‐  ‐  ‐
1+  ‐  2+  ‐ 3+  ‐  ‐  ‐  ‐  ‐  +  +  +  ‐  ‐  ‐  ‐ 36  ‐  ‐  ‐  ‐
 ‐ 2+  ‐ 2+  ‐  ‐  ‐  +  + ‐ ‐ ‐ ‐ ‐ ‐  +  + 37 ‐ ‐ ‐ ‐
 ‐  ‐ 3+  ‐ 3+  ‐  ‐  ‐  ‐  +  +  +  +  ‐  ‐  ‐  ‐ 38  ‐  ‐  ‐  ‐
 ‐  2+  ‐  ‐  ‐  ‐  ‐  +  +  ‐  ‐  ‐  ‐  ‐  ‐  ‐  ‐ 39  ‐  ‐  ‐  ‐
     ‐    ‐ 2+   ‐ 2+  ‐  ‐   ‐  ‐  ‐  ‐  +  +   ‐  ‐  ‐  ‐ 40  ‐  ‐  ‐  ‐
‐ 2+ ‐ 4+ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ 41 ‐ ‐ ‐ ‐
1+ 2+ 2+ 2+ 2+ + + + + ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ 42  +  +  +  +
‐ ‐ ‐ 2+ 2+ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐  + 43 ‐ ‐ ‐ ‐
‐ 2+ ‐ 2+ ‐  ‐  ‐  +  +  ‐  ‐  ‐  ‐  ‐  ‐  +  + 44  ‐  ‐  ‐  ‐
‐ 3+ 3+ 3+ 1+  +  ‐  ‐  +  ‐  ‐  ‐   +  +  ‐  +  + 45  ‐  ‐  ‐  +
1+ ‐ 2+ 1+ 2+  ‐   +  ‐  ‐  ‐  +  +  ‐  ‐  ‐  ‐  ‐ 46  ‐  +  +  +
‐ 2+ 3+ 2+ 3+  ‐  ‐  +  +  +  ‐  ‐  +  ‐  ‐  ‐  + 47  ‐  ‐  +  +
‐ ‐ 2+ 2+ 2+ ‐  + + + + ‐ ‐ ‐ ‐ ‐ ‐ ‐ 48 ‐ ‐ ‐ ‐
+ ‐ ‐ 1+ 2+ ‐ ‐ + ‐ ‐ + + ‐ ‐ ‐ ‐ ‐ 49 ‐ + + ‐
‐ 1+ 2+ 2+ 1+ + ‐ + ‐ + + + + ‐ ‐ ‐ ‐ 50 ‐ ‐ ‐ ‐
SNOW BANKING SNOW BANKING
S.NO.
RE
MENT
LE
SNOWBALL OPACITY
VITREOUS OPACITY RELEVITREOUS CELLS
UT  UN LN LT UT UN LN LT RE LE CME UT UN LN LT UT UN
 ‐  ‐  ‐  ‐  ‐  ‐  ‐  ‐  ‐  +  ‐ 1 Mi(LE)  ‐  ‐  ‐  ‐  ‐  ‐
 ‐  ‐  +  +  ‐  ‐  ‐  ‐  ‐  ‐ PVD (BE) , DE (RE) 2  ‐  ‐  ‐  +  +  ‐  ‐
 ‐  ‐  ‐  ‐  ‐  ‐  ‐  ‐  ‐  ‐  ‐ 3  ‐  ‐  ‐  ‐  ‐  ‐  ‐
 ‐  ‐  ‐  ‐  ‐  ‐  ‐  ‐  ‐  ‐  ‐ 4  ‐  ‐  ‐  ‐  ‐  ‐  ‐
 ‐  ‐  ‐  ‐  ‐  ‐  ‐  ‐   +  ‐  PVD(LE), ERM (LE) 5 Mo(RE)  ‐  ‐  ‐  ‐  ‐  ‐
  ‐   ‐  ‐  ‐  ‐  ‐  ‐  ‐   ‐   ‐  ‐ 6  ‐  ‐  ‐  ‐  ‐  ‐  ‐
 ‐  ‐  ‐  ‐  ‐  ‐  ‐  ‐  ‐   ‐  ‐ 7  ‐  ‐  ‐  ‐  ‐  ‐  ‐
 ‐  ‐  ‐  ‐   ‐   ‐   ‐   ‐   ‐   ‐   ‐ 8  ‐  ‐  ‐  ‐  ‐  ‐  ‐
 ‐  ‐  ‐  ‐  ‐  ‐  ‐  ‐  +  ‐  ‐   9 Mi(RE)  ‐  ‐  ‐  ‐  ‐  ‐
 ‐  ‐  ‐  ‐  ‐  ‐  ‐  ‐  ‐  ‐ PVD (BE)  10  ‐  ‐  ‐  ‐  ‐  ‐  ‐
 ‐  ‐   ‐  ‐  ‐  ‐  ‐  ‐  ‐  ‐  ‐ 11  ‐  ‐  ‐  ‐  ‐  ‐  ‐
 ‐  ‐  ‐  ‐  ‐  ‐  ‐  ‐  ‐  +  ‐ 12 Mi(LE)  ‐  ‐  ‐  ‐  ‐  ‐
 ‐  ‐  ‐  ‐  ‐  ‐  ‐  ‐  ‐  ‐  ‐ 13  ‐  ‐  ‐  ‐  ‐  ‐  ‐
‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐  + ‐ ‐ 14  Mi(RE) ‐ ‐ ‐ ‐ ‐ ‐
 ‐  ‐  ‐  ‐  ‐  ‐  ‐  ‐  ‐  ‐  ‐ 15  ‐  ‐  ‐  ‐  ‐  ‐  ‐
 ‐  ‐  ‐  ‐  +  ‐  ‐  +  ‐  +  ‐   16 Mo(LE)  ‐  ‐  ‐  ‐  +  ‐
 ‐  ‐  ‐  ‐  ‐  ‐  ‐  ‐  ‐  +  ‐ 17 Mi(LE)  ‐  ‐  ‐  ‐  ‐  ‐
‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ 18 N  + ‐  +  + ‐ ‐
  ‐  ‐  ‐  ‐  ‐  ‐  ‐  ‐  ‐  ‐  ‐ 19  ‐  ‐  ‐  ‐  ‐  ‐  ‐
 ‐  ‐  ‐  ‐  ‐  ‐  ‐  ‐  ‐  ‐  ‐ 20  ‐  ‐  ‐  ‐  ‐  ‐  ‐
 ‐  ‐  ‐  ‐  ‐  ‐  ‐  ‐  +  ‐  ‐ 21 Mi(RE)  ‐  ‐  ‐  ‐  ‐  ‐
+ ‐ ‐ ‐ + + + + ‐  + ‐ 22 Mi(LE)  ‐  ‐  ‐  ‐  +  +
 ‐  ‐  ‐  ‐  ‐  ‐  ‐  ‐  ‐  ‐  ‐ 23  ‐  ‐  ‐  ‐  ‐  ‐  ‐
 ‐  ‐  ‐  ‐  ‐  ‐  ‐  ‐  ‐  ‐  ‐ 24  ‐  ‐  ‐  ‐  ‐  ‐  ‐
 ‐  ‐  ‐  ‐  ‐  ‐  ‐  ‐  ‐  + PVD(LE) 25 Mi(LE)  ‐  ‐  ‐  ‐  ‐  ‐
 +  +  +  +  ‐  ‐  ‐  ‐  +  ‐ HMD(RE) 26 Mi(RE)  +  +  +  +  ‐  ‐
 ‐  ‐  ‐  ‐  ‐  ‐  ‐  ‐  ‐  ‐  ‐ 27  ‐  ‐  ‐  ‐  ‐  ‐  ‐
  ‐   ‐   ‐   ‐   ‐   ‐   ‐   ‐   ‐  +  ‐ 28 Mi(LE)  ‐  ‐  ‐  ‐  ‐  ‐
 ‐  ‐  ‐  ‐  ‐  ‐  ‐  ‐  +  + PVD(BE) 29 Mi(BE)  ‐  ‐  ‐  ‐  ‐  ‐
 ‐  ‐  ‐  ‐  ‐  ‐  ‐  ‐  ‐  ‐  ‐ 30  ‐  ‐  ‐  ‐  ‐  ‐  ‐
 ‐  ‐  ‐  ‐  ‐  ‐  ‐  ‐  ‐  ‐  ‐ 31  ‐  ‐  ‐  ‐  ‐  ‐  ‐
 ‐  ‐  ‐  ‐  ‐  ‐  ‐  ‐  ‐  ‐  ‐ 32  ‐  ‐  ‐  ‐  ‐  ‐  ‐
+ ‐ ‐ ‐ + + + + ‐ Mi ‐ 33 ‐  ‐  ‐  ‐  ‐  +  +
 ‐  ‐  ‐  ‐  ‐  ‐  ‐  ‐  ‐  ‐  ‐ 34  ‐  ‐  ‐  ‐  ‐  ‐  ‐
 ‐  ‐  ‐  ‐  ‐  ‐  ‐  ‐  ‐  ‐  ‐ 35  ‐  ‐  ‐  ‐  ‐  ‐  ‐
 ‐  ‐  ‐  ‐  ‐  +  ‐  ‐  ‐  ‐  ‐ 36  ‐  ‐  ‐  ‐  ‐  ‐  ‐
‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐  + ‐ ‐ 37  Mi(RE) ‐ ‐ ‐ ‐ ‐ ‐
 ‐  ‐  ‐  ‐  ‐  ‐  ‐  ‐  ‐  ‐  ‐ 38  ‐  ‐  ‐  ‐  ‐  ‐  ‐
 ‐  ‐  ‐  ‐  ‐  ‐  ‐  ‐  +  ‐  ‐   39 Mi(RE)  ‐  ‐  ‐  ‐  ‐  ‐
 ‐  ‐  ‐  ‐  ‐  ‐  ‐  ‐  ‐  +  ‐ 40 Mi(LE)  ‐  ‐  ‐  ‐  ‐  ‐
‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ 41 N  + ‐  +  + ‐ ‐
 ‐ ‐ + ‐ + + + + ‐ Mi ‐ 42 Mi(LE) ‐ ‐ ‐ ‐ ‐ ‐
‐ ‐ ‐ ‐ ‐ ‐ ‐ + Mi ‐ 43 Mi(RE) ‐ ‐ ‐ + ‐ ‐
 ‐  ‐  ‐  ‐  ‐  ‐  ‐  ‐  ‐  ‐  ‐ 44  ‐  ‐  ‐  ‐  ‐  ‐  ‐
 ‐  ‐  +  +  ‐  ‐  ‐  ‐  ‐ Mi  ‐ 45 Mi(RE)  ‐  ‐  +  ‐  ‐  ‐
 ‐  ‐  ‐  ‐  ‐  +  +  ‐  ‐ Mo  ‐ 46 Se(LE)   ‐  ‐  ‐  ‐  ‐  ‐
 ‐  ‐  ‐  ‐  ‐  ‐  +  + Mi Mo  ‐ 47 Mi(BE)  ‐  ‐  ‐  ‐  ‐  ‐
‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ Mi ‐ ‐ 48 Mi(RE)  ‐  ‐  ‐  ‐  ‐  ‐
‐ ‐ ‐ ‐  ‐ + ‐ ‐ ‐ Mi ‐ 49 Mi(LE)  ‐  ‐  ‐  ‐  ‐  ‐
+ ‐ ‐ ‐ + + + + ‐ Mi ‐ 50 ‐  ‐  ‐  ‐  ‐  +  +
DISC & VITREOUS
FFA                       VASCULITIS
RE L
S.NO.
VASCULITIS
RE LE CME
LN LT RE LE 1 WEEK 2 WEEKS 1 MONTH RE LE D‐Months RE LE
 ‐  ‐   6/6  6/12  ‐  +  ‐  ‐ 1  ‐  ‐  ‐  ‐  6/6  6/9 4  N  N
 ‐  ‐  6/18  6/12  ‐  +  +  ‐ 2  ‐  ‐  ‐  ‐  6/9  6/6 10  MH  N
 ‐  ‐    6/60   6/36  ‐  +  ‐  ‐ 3  ‐  ‐  ‐  ‐     6/24    6/12 8  MH   MH
 ‐  ‐  6/6   6/18   ‐  +   +  ‐ 4   ‐   ‐   ‐   ‐   6/6     6/9 6  N   N
 ‐  ‐     6/60     6/24  PSCC(BE),↑IOP  ‐  +  +  ‐ 5  ‐    ‐  ‐  ‐         6/36        6/18 12    HV     St
 ‐  ‐     6/6   6/24  PSCC(LE)  ‐   +  +  ‐ 6  ‐  ‐  ‐   ‐      6/6       6/12 8    N   MH
 ‐  ‐        6/18        6/6 ↑IOP,HM   ‐  +  ‐  ‐ 7   ‐   ‐  ‐  ‐       6/12     6/6 5    MH    N
 ‐  ‐    6/6      6/60  ‐  ‐   +   +  ‐ 8  ‐  ‐   ‐   ‐     6/6     6/36 6     N    MoH
 ‐  ‐     6/12     6/6   ‐     ‐   +  +  ‐ 9  ‐  ‐  ‐  ‐      6/12   6/6 3     MoH   N
 ‐  ‐     1/60    6/24 ↑IOP, Vit Hmg  ‐  +  +  + 10  ‐  ‐  ‐  ‐    6/36    6/18 10    St    MH
 ‐  ‐     6/60      6/12  ‐  ‐   ‐  +  ‐  ‐ 11  ‐  ‐  ‐  ‐   6/24   6/9 5     MH   N
 ‐  ‐   6/6    6/36  ‐  ‐  +  +  ‐ 12  ‐  ‐  ‐  ‐   6/6    6/12 4  N  MH
 ‐  ‐     5/60      2/60   PSCC(BE)  ‐  +  +  ‐ 13  ‐  ‐  ‐  ‐   6/60   5/60 3  HV  HV
‐ ‐       6/60       6/6  ‐  ‐  +  ‐  ‐ 14 ‐ ‐ ‐ ‐   6/18   6/6 3   MH N
 ‐  ‐  6/36      6/36 PSCC(BE)  ‐  +  +   ‐ 15  ‐  ‐  ‐  ‐     6/18    6/9 4  MH N
 ‐  +    6/6   6/18  ‐  ‐  +  +  ‐ 16  ‐  ‐  ‐  ‐   6/6    6/9 8 N  N
 ‐  ‐   6/6  6/36  ‐ ‐  +  ‐  ‐ 17  ‐  ‐  ‐  ‐  6/6   6/12 4  N  N
‐ ‐   3/60     6/6 ‐ ‐ + +  ‐ 18 ‐ ‐ ‐ ‐ ‐    6/36    6/6 10  MH N
 ‐  ‐      6/24       6/24 PSCC(BE)  ‐  +  +  ‐ 19 ‐ ‐ ‐ ‐    6/12     6/12 6    MH MH
 ‐  ‐   5/60      2/60  ‐  ‐  +  +  ‐ 20  ‐  ‐  ‐  ‐     6/18     6/36 10  N  N
 ‐  ‐      6/18    6/6  ‐  ‐  +  +  ‐ 21  ‐  ‐  ‐  ‐    6/9    6/6 8   N   N
 +  +   6/6    4/60 PSCC(BE) ‐ + +  ‐ 22 360°(LE)  5/60  6/60  6/60   6/6    6/36 4 N MH
 ‐  ‐       1/60      6/60  ‐  ‐  +  +  ‐ 23  ‐  ‐  ‐  ‐   6/60    6/36 3  HV HV
 ‐  ‐   6/18    6/12  ‐  ‐  +  +  ‐ 24  ‐  ‐  ‐  ‐   6/12   6/9 6  MH N
 ‐  ‐   6/6   6/36  ‐  ‐  +  +  ‐ 25  ‐  ‐  ‐  ‐    6/6    6/12 8  N  N
 ‐  ‐   6/36    6/18  ‐  ‐  +  +  ‐ 26  ‐  ‐  ‐  ‐   6/36   6/18 4  HV  HV
 ‐  ‐    6/12     6/18  ‐   +  ‐  ‐ 27  ‐  ‐  ‐  ‐   6/12   6/12 5  MH  HV
 ‐  ‐    6/6     6/60  ‐  ‐  +  +  ‐ 28  ‐  ‐  ‐  ‐   6/6    6/12 3  N  N
 ‐  ‐    1/60    6/60  ‐  ‐  +  +  ‐ 29  ‐  ‐  ‐  ‐    6/36    6/24 6   MH  MH
 ‐  ‐    6/9   6/6  ‐  +  ‐  ‐  ‐ 30  ‐  ‐  ‐  ‐   6/6   6/6 4  N N
 ‐  ‐    6/60     6/6  PSCC(RE)  ‐  +  ‐  ‐ 31  ‐  ‐  ‐  ‐     6/12    6/6 6  MH  N
 ‐  ‐    1/60    1/60  ‐  ‐  +  +  ‐ 32  ‐  ‐  ‐  ‐      6/18    6/36 4   N  MH
 +  +   6/6    4/60 PSCC(BE) ‐ + +  ‐ 33 360°(LE)  6/60  6/60  6/36   6/6    6/36 4 N MH
 ‐  ‐   6/12    6/6  ‐  ‐  +  ‐  ‐ 34  ‐  ‐  ‐  ‐   6/6   6/6 3  N  N
 ‐  ‐    6/12   6/18  ‐  ‐  +  +  ‐ 35  ‐  ‐  ‐  ‐   6/9   6/9 7  N  N
 ‐  ‐  NO PL   6/12  ‐  +  ‐  ‐  + 36  ‐  ‐  ‐  ‐ NO PL  6/6 24  ‐  N
‐ ‐  6/36       6/6  ‐  +   +  ‐ 37 ‐ ‐ ‐ ‐   6/9   6/6 6  N N
 ‐  ‐   6/6   6/60  ‐  ‐  +  +  ‐ 38 360°(LE)  6/60   6/36  6/36   6/6  6/24 10  N  MH
 ‐  ‐     6/12     6/6   ‐     ‐   +  +  ‐ 39  ‐  ‐  ‐  ‐   6/9   6/6 3  N   N
 ‐  ‐   6/6  6/18  ‐ ‐  +  ‐  ‐ 40  ‐  ‐  ‐  ‐  6/6  6/9 4  N  N
‐ ‐   3/60     6/6 ‐ ‐ + +  ‐ 41 ‐ ‐ ‐ ‐ ‐   6/6    6/6 10 N N
‐ ‐    6/24     6/36 ‐ ‐ + +  ‐ 42 360°(RE)LN(LE) 5/60|6/36   6/36(BE)  6/36(BE)   6/18    6/18 12 St St
‐ ‐  6/12  6/9 ‐ ‐ + +  ‐ 43  ‐  ‐ ‐ ‐  6/9  6/6 18 N N
 ‐  ‐    6/36    6/6  ‐  ‐  +  +  ‐ 44  ‐  ‐  ‐  ‐    6/36     6/6 5 St  ‐
 ‐  ‐    6/24    6/36  ‐  ‐  +  +  ‐ 45  ‐  ‐  ‐  ‐     6/12      6/18 3  HV  HV
 +  ‐    6/9    6/60  ‐  ‐  +  +  ‐ 46 UNLNLT(LE)  6/60  6/60  6/36     6/6      6/36 4 LFU  ‐
 ‐  ‐    6/36    6/60  ‐  ‐  +  +  ‐ 47  ‐  ‐  ‐  ‐    6/36      6/60 1 LFU  ‐
 ‐  ‐   6/36   6/60  ‐   ‐ + +  ‐ 48 ‐ ‐ ‐ ‐     6/12     6/12 8 N N
 ‐  ‐   6/6    6/24  ‐ ‐ + ‐  ‐ 49 ‐ ‐ ‐ ‐   6/6     6/6 16 N N
 +  +   6/6   6/60 ‐ + +  ‐ 50 ‐ ‐ ‐ ‐   6/6    6/12 4 N MH
V/A EFE
S.NO.COMMENTS
C V/A ‐ Ad
IS
V/A AFTER CRYO
O S/T S SS CRYO
SUBJECTIVE E.F
RE LE RE LE RE LE RE LE RE LE RE LE RE LE
 ‐  ‐  ‐  ‐  ‐  ‐  ‐  ‐ 1  ‐  +  ‐    ‐  ‐ Ia
 ‐  ‐  ‐  ‐  ‐  ‐  ‐  ‐  2  ‐  ‐  ‐  ‐ II II
 ‐   ‐   ‐   ‐   ‐  ‐   ‐   ‐ 3   ‐   ‐   ‐   ‐ Ib Ib
  ‐    ‐   ‐    ‐   ‐   ‐    ‐    ‐ 4     ‐   ‐   ‐    ‐  ‐ Ia
 ‐   ‐    ‐    ‐   ‐    ‐   ‐   ‐ 5   ‐   ‐ Mi    ‐ Ia II
 ‐  ‐   ‐   ‐  ‐  ‐  ‐  ‐ 6  ‐  ‐  ‐  ‐  ‐ Ia
 ‐  ‐  ‐  ‐  ‐  ‐  ‐    ‐ 7   ‐   ‐   ‐   ‐ Ia  ‐
  ‐   ‐   ‐   ‐   ‐   ‐   ‐   ‐ 8   ‐   +  ‐  ‐  ‐ Ib
 ‐  ‐   ‐   ‐   ‐   ‐   ‐   ‐ 9   ‐   ‐  ‐  ‐ Ia  ‐
 ‐  ‐  ‐ 1+  ‐ 1+  ‐  ‐ 10  ‐  +  ‐  ‐ II II
 ‐  ‐  ‐  ‐  ‐  ‐   +  ‐ 11  ‐  ‐  ‐  ‐ Ia  ‐
 ‐  ‐  ‐  ‐  ‐  ‐  ‐  ‐ 12  ‐  ‐  ‐ Mi  ‐ Ia
 ‐  ‐  ‐  ‐ 1+ 1+  +  + 13  ‐  ‐  ‐  ‐ II II
 ‐  ‐  ‐  ‐ 1+  ‐  ‐  ‐ 14  ‐  ‐  ‐  ‐ Ib  ‐
 ‐  ‐  ‐  ‐ 1+  ‐  ‐  ‐ 15  ‐  ‐  ‐  ‐ Ib Ib
 ‐  +  ‐  ‐  ‐ 1+  ‐  ‐ 16  ‐  ‐  ‐  ‐  ‐ III
 ‐  ‐  ‐  ‐  ‐  ‐  ‐  ‐ 17  ‐  +  ‐    ‐  ‐ Ia
‐ ‐ ‐ ‐ 2+ ‐ ‐ ‐ 18 ‐ ‐ ‐ ‐ Ib ‐
 ‐  ‐  ‐ 1+ ‐ ‐ ‐ ‐ 19 ‐ ‐ ‐ ‐ Ia Ia
 ‐  ‐  ‐  ‐  ‐  ‐  ‐  ‐ 20  ‐  ‐  ‐  ‐ Ia Ib
 ‐  ‐  ‐  ‐  ‐  ‐  ‐  ‐ 21  ‐  ‐  ‐  ‐ Ia  ‐
 ‐ + 1+ 2+ 1+ 1+ ‐ + 22 ‐ ‐ ‐ Mi Ia III
 ‐  ‐  ‐  ‐  ‐  ‐  ‐  ‐ 23  +  +  ‐  ‐ Ib Ib
 ‐  ‐  ‐  ‐  ‐  ‐  ‐  ‐ 24  ‐  ‐  ‐  ‐ Ia Ia
 ‐  ‐  ‐  ‐  ‐  ‐  ‐  ‐ 25  ‐  ‐  ‐  ‐  ‐ II
 +  ‐  +  ‐  +  ‐  ‐  ‐ 26  ‐  ‐ Mi    ‐ III  ‐
 ‐  ‐  ‐  ‐  ‐ 1+  ‐  ‐ 27  ‐  ‐  ‐  ‐ Ia Ia
 ‐  ‐  ‐  ‐  ‐  +  ‐  ‐ 28  ‐  ‐  ‐  ‐  ‐ Ia
 ‐  ‐  ‐  ‐ 1+ 1+  ‐  ‐ 29  ‐  ‐  Mi  ‐ II  II
 ‐  ‐  ‐  ‐  ‐  ‐  ‐  ‐ 30  ‐  ‐  ‐  ‐ Ia  ‐
 ‐  ‐  1+  ‐  ‐  ‐  ‐  ‐ 31  ‐  ‐  ‐  ‐ Ia   ‐
 ‐  ‐  ‐  ‐ 1+ 1+  ‐  ‐ 32  ‐  ‐  ‐  ‐ Ib Ib
 ‐ + 1+ 2+ 1+ 1+ ‐ + 33 ‐ ‐ ‐ Mi Ia III
 ‐  ‐  ‐  ‐  ‐  ‐  ‐  ‐ 34  ‐  ‐  ‐  ‐ Ia  ‐
 ‐  ‐  ‐  ‐  ‐  ‐  ‐  ‐ 35  ‐  ‐  ‐  ‐ Ia Ia
 ‐  ‐  ‐  ‐  ‐  ‐  ‐  ‐ 36  ‐  ‐  ‐  ‐  ‐ Ib
 ‐  ‐  ‐  ‐  ‐  ‐  ‐  ‐ 37  ‐  ‐  ‐  ‐ Ia  ‐
 ‐  ‐  ‐  ‐  ‐  +  ‐  ‐ 38  ‐  ‐  ‐  ‐  ‐ Ib
 ‐  ‐   ‐   ‐   ‐   ‐  +   ‐ 39   ‐   ‐  ‐  ‐ Ia  ‐
 ‐  ‐  ‐  ‐  ‐  ‐  ‐  ‐ 40  ‐  +  ‐    ‐  ‐ Ia
‐ ‐ ‐ ‐ 2+ ‐ ‐ ‐ 41 ‐ ‐ ‐ ‐ Ib ‐
‐ ‐ ‐ ‐  + ‐ ‐ ‐ 42 ‐ ‐ ‐ Ib II
‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ 43 ‐ ‐ ‐ ‐ Ib Ia
 ‐  ‐  ‐  ‐  ‐  ‐  ‐  ‐ 44  ‐  ‐  ‐  ‐  II  ‐
 ‐  ‐  +  +  +  +  +  + 45  ‐  ‐ Mi  ‐ Ib Ib
 ‐  ‐  + 2+ 2+  ‐  ‐  ‐ 46  ‐  ‐ Mo  ‐ Ib II
 ‐  ‐  ‐  ‐  ‐  ‐  ‐  ‐ 47  ‐  ‐  ‐  ‐ Ib Ib
‐ ‐ ‐ ‐ ‐ + ‐ ‐ 48 ‐ ‐ ‐ ‐ Ia Ia
‐ ‐ ‐ ‐ ‐ + ‐ ‐ 49 ‐ ‐ ‐ ‐ Ia Ib
 ‐ + 1+ 2+ 1+ 2+ ‐ + 50 ‐ ‐ ‐ Mi Ia Ib
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